General Mills čeká 1. července růst tržeb i zisku za 4. čtvrtletí, s odhadem tržeb 4,6 miliardy USD a EPS 82 centů. Tahounem má být značka Blue Buffalo a zlepšení marží.
Key Takeaways General Mills is likely to see Q4 revenues and earnings rise when it reports results on July 1, 2026. GIS' Remarkability strategy is supporting demand, distribution and share trends in key retail categories. GIS may gain from Blue Buffalo momentum, margin programs, and easing trade and supply-chain headwinds. General Mills, Inc. (GIS - Free Report) is likely to witness top and bottom-line growth when it reports fourth-quarter fiscal 2026 earnings on July 1. The Zacks Consensus Estimate for revenues is pegged at $4.6 billion, indicating an increase of nearly 1% from the prior-year quarter’s reported figure.
The consensus mark for earnings has remained unchanged over the past 30 days at 82 cents a share, which implies 10.8% growth from the figure reported in the year-ago period. GIS has a trailing four-quarter earnings surprise of 1.2%, on average.
Factors Likely to Influence GIS’ Upcoming ResultsGeneral Mills’ fourth-quarter performance is likely to have witnessed improving business momentum as the company continues executing its Remarkability strategy through product innovation, enhanced consumer value, stronger brand communication and improved omnichannel execution. These initiatives have been driving better household penetration, baseline demand, distribution and market-share trends across several key North America Retail categories.
Management has indicated that the investments made earlier in the fiscal year are expected to support a step-up in organic sales trends during the fourth quarter, aided by stronger competitiveness and seasonal merchandising opportunities.
The North America Pet business is also expected to remain a growth contributor, supported by continued momentum in Blue Buffalo, expanding distribution of Love Made Fresh and ongoing innovation across the pet portfolio. Management expects retailer inventory trends, which weighed on prior-quarter shipments, to normalize in the fourth quarter. Together with continued market-share gains, these factors are likely to support healthier revenue trends across the business. Our model suggests fourth-quarter organic sales growth of 1.4% for the North America Pet segment.
On the earnings front, General Mills is expected to benefit from its Holistic Margin Management program and Global Transformation initiatives. Management also expects several temporary headwinds that weighed on results earlier in the fiscal year, including unfavorable trade-expense timing and weather-related supply-chain disruptions, to become tailwinds in the fourth quarter, supporting a sequential improvement in operating performance and earnings. We expect the adjusted operating margin to increase 60 basis points to 14.3% in the fourth quarter.
However, persistent consumer caution, elevated input costs, tariff-related inflation and ongoing value investments aimed at strengthening competitiveness may have tempered profitability during the quarter despite improving underlying business trends.
Q4 Earnings Whispers for GISOur proven model doesn’t conclusively predict an earnings beat for General Mills this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
General Mills currently carries a Zacks Rank #4 (Sell) and has an Earnings ESP of +0.21%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable CombinationHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Kimberly-Clark Corporation (KMB - Free Report) currently has an Earnings ESP of +0.39% and a Zacks Rank of 3. The Zacks Consensus Estimate for Kimberly-Clark’s upcoming quarterly revenues is pegged at $4.23 billion. The figure implies a 1.7% increase from the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Kimberly-Clark’s quarterly earnings per share is pegged at $1.99, indicating a 3.7% gain from the year-ago period figure. KMB delivered a trailing four-quarter earnings surprise of 19.1%, on average.
Celsius Holdings, Inc. (CELH - Free Report) currently has an Earnings ESP of +1.30% and a Zacks Rank of 3. The consensus estimate for CELH’s quarterly revenues is pinned at $891.5 million, which calls for 20.6% growth from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for Celsius Holdings’ upcoming quarter’s EPS is pegged at 42 cents, which implies a 10.6% decrease year over year. CELH delivered a trailing four-quarter earnings surprise of 58.1%, on average.
Tyson Foods, Inc. (TSN - Free Report) currently has an Earnings ESP of +2.17% and a Zacks Rank of 3. The consensus estimate for Tyson Foods’ quarterly revenues is pinned at $14.29 billion, which suggests 2.9% growth from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for the upcoming quarter’s EPS is pegged at $1.04, which implies a 14.3% increase year over year. TSN delivered a trailing four-quarter earnings surprise of nearly 18.1%, on average.
Costco říká, že AI vyhledávání je zatím malé, ale ve třetím čtvrtletí vzrostlo trojciferně a mělo nejvyšší konverzi ze všech zdrojů návštěvnosti. Digitální návštěvnost webu a aplikace stoupla o 37 % a digitálně podpořené srovnatelné tržby vzrostly o 21,5 %.
Key Takeaways Costco is using AI search to make its products and member value easier for consumers to find.AI traffic remains low but grew triple digits in Q3 and had the highest conversion rate.Digital engagement is strong, with site and app traffic up 37%, and digital comps up 21.5%. Costco Wholesale Corporation (COST - Free Report) suggests that artificial intelligence (AI) is a small but important digital opportunity, even at this early stage. Management said consumers are increasingly using AI to research products and services, and Costco is working with leading AI companies to improve how its value proposition is presented to current and potential members. The strategy is not about changing the core model. It is about making Costco products easier to find through AI search.
The key step is to improve online product pages so that large language models can better capture Costco’s quality, pricing and member value. This matters because some Costco offers are hard to explain through a regular search. Management pointed to appliances, where the real value includes delivery, installation and haul-away and to tires, where installation, road hazard coverage and nitrogen are included. AI search can present that broader value more clearly.
The early signals are notable. AI-generated traffic remains low, but Costco saw triple-digit growth in the third quarter of fiscal 2026, and this traffic carried the highest conversion rate of any source coming to its site. That sits alongside strong digital engagement, with site and app traffic up 37% and digitally enabled comparable sales up 21.5%. AI search is not yet a major revenue engine, but it could become a useful driver for Costco’s digital business.
What the Latest Metrics Say About CostcoCostco, which competes with Dollar General Corporation (DG - Free Report) and Target Corporation (TGT - Free Report) , has seen its shares drop 4.5% over the past three months compared with the industry’s 0.2% decline. Shares of Dollar General and Target have jumped 1.4% and 18.1%, respectively, in the aforementioned period.
Image Source: Zacks Investment Research
From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 43.11, higher than the industry’s ratio of 30.91. However, it is trading below its 12-month median level of 46.40, indicating some moderation in valuation despite sustained investor confidence in the stock.
Costco is trading at a premium to Target (with a forward 12-month P/E ratio of 16.38) and Dollar General (15.71).
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Costco’s current financial-year sales and earnings per share implies year-over-year growth of 9.4% and 13.3%, respectively. For the next fiscal year, the consensus estimate indicates a 7.8% rise in sales and 10.2% growth in earnings.
The consensus estimate for earnings per share for the current and next fiscal year has increased by 5 cents and 6 cents to $20.38 and $22.46, respectively, over the past 30 days.
Image Source: Zacks Investment Research
Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
SummaryMicron delivered another record-breaking quarter, with Q3 revenue surging to nearly $41.5 billion on exceptional pricing strength.Non-GAAP gross margins soared to nearly 85%, more than doubling year-over-year, driving adjusted EPS to $25.11 versus $1.91 last year.Management guided Q4 revenue to $50 billion, well above consensus, with gross margins expected to rise further to 86% as price increases moderate.MU generated $18.3 billion in adjusted free cash flow, reduced debt by 40%, and plans to return 100% of excess cash to shareholders over time. Tim Robberts/DigitalVision via Getty Images
As companies try to pivot to a future of Artificial Intelligence, there have been a number of clear winners in the market. One of the biggest has been Micron Technology, Inc. (MU), with
38.33K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Investors are always reminded that before making any investment, you should do your own proper due diligence on any name directly or indirectly mentioned in this article. Investors should also consider seeking advice from a broker or financial adviser before making any investment decisions. Any material in this article should be considered general information, and not relied on as a formal investment recommendation.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
JPMorgan ponechává pro Broadcom cílovou cenu 580 USD a očekává růst tržeb z AI čipů každý rok až do roku 2031. Banka tvrdí, že TPU v9 je stále na cestě k rozjezdu v roce 2028.
This is a fair market value price provided by Massive. Learn more.
52-Week Range$262.66▼
$495.00Dividend Yield0.72%
P/E Ratio60.61
Price Target$493.24
Semiconductor giant Broadcom NASDAQ: AVGO experienced a dramatic drop-off since its last earnings report. Just days prior to the release, Broadcom traded at its all-time high near $480. However, the company failed to meet the extremely high expectations implied by its valuation, and shares tanked almost 20% in the following two days.
Amid this, one Wall Street firm coming to Broadcom’s defense is JPMorgan Chase & Co. The bank and its analyst, Harlan Sur, have a $580 price target on Broadcom. This is among the highest on Wall Street and far exceeds the MarketBeat consensus target near $493.
Get Broadcom alerts:
Notably, Sur recently reiterated his highly bullish target on Broadcom. Sur also provided key commentary for his rationale that paints a very positive picture of Broadcom’s relationship with its most important customer.
Broadcom and Alphabet: The Hot Button TPU DebateOne of the concerns coming out of Broadcom’s last earnings call was the future of its relationship with Google parent company Alphabet NASDAQ: GOOGL. Alphabet is widely believed to be Broadcom’s largest custom artificial intelligence (AI) chip customer.
The two firms have collaborated on multiple generations of Alphabet’s tensor processing units (TPUs) for several years. This is a core partnership that has helped Broadcom become the world’s second-largest semiconductor company, only behind NVIDIA NASDAQ: NVDA. Thus, when thinking about Broadcom’s outlook, investors are keenly aware of anything that points to volatility in its relationship with Alphabet.
In this context, a quote from Broadcom CEO Hock Tan from the company’s last earnings call was somewhat troubling. Tan noted, “Given the growth of consumption and development and consumption of AI compute, even by our partner, Google, that we fully expect that there will be some diversity of sources for them.” In other words, Google’s TPU program is becoming so large that Broadcom does not expect to be the only partner involved with it going forward.
Notably, industry analysts believe that the Taiwanese company MediaTek OTCMKTS: MDTKF is also a TPU partner. However, analysts debate the size of this partnership and the specific TPU variants that MediaTek is working on.
JPMorgan Shows Confidence in Broadcom’s TPU LeadershipConsidering this, JPMorgan’s analysis is positive for Broadcom. Currently, Google is on its eighth generation TPU, TPU v8, which features multiple variants. JPMorgan says that the five-year agreement that Google and Broadcom signed in March “locks in Broadcom’s TPU design win roadmap for the next four generations of TPU chips through v11.” JPMorgan also believes this means that Broadcom’s TPU revenues will increase annually through 2031. Furthermore, JPMorgan argues that investors should dismiss reports of delays in the TPU v9 program, saying that TPU v9 is on track to ramp up in 2028.
This pushes back on other reporting that Broadcom’s TPU v9 progress is facing delays. These reports argue that Broadcom has “lost its leading position," which has allowed MediaTek to win major orders for the TPU v9.
For its part, JPMorgan is showing a fairly significant amount of confidence that Broadcom remains in pole position within Google’s TPU program. The firm demonstrates this by reiterating its $580 target—a level that many Wall Street targets sit well below.
Additionally, there is real disagreement around MediaTek’s specific involvement with Google. JPMorgan argues that Broadcom is developing the inference-optimized TPU v8i, while MediaTek is working on the training-optimized TPU v8t. Other industry reports point to MediaTek designing the v8i and Broadcom designing the v8t.
Beyond the Rumors: Broadcom’s AI Chip Business Continues to ExplodeFor investors, there are several key takeaways. First off, reports among these various sources contradict one another. This is true regarding potential delays with Broadcom’s TPU v9 and which variants Broadcom and MediaTek are working on in the TPU v8. Thus, at this point, it is best to focus on facts and the points of general consensus.
Overall MarketRank™100th Percentile
Analyst RatingModerate Buy
Upside/Downside35.1% Upside
Short Interest LevelHealthy
Dividend StrengthStrong
News Sentiment1.17 Insider TradingSelling Shares
Proj. Earnings Growth71.97%
See Full Analysis
Broadcom has been working with Google for a long time. Broadcom expects its AI semiconductor revenue to rise by over 200% year over year next quarter to $16 billion. Meanwhile, just months ago, Google and Broadcom entered a long-term agreement for Broadcom to develop and supply future generations of TPUs. In its fiscal year 2027, Broadcom expects to generate more than $100 billion in AI semiconductor revenue.
However, all cited reports state that MediaTek is also involved in TPU development. Hock Tan did little to push back on this with its recent statement. MediaTek also recently raised its custom AI chip revenue forecast in 2026 to $2 billion. It estimates that this market will be worth $70 billion to $80 billion in 2027. The company is targeting 10% to 15% of that total in the coming years, implying an opportunity well above $2 billion. Still, Broadcom’s AI chip business is far larger today and is growing extremely fast.
Overall, with limited clarity today, the relationship between Google, Broadcom, and MediaTek is a risk to watch going forward, but not worth the panic. In the meantime, one of Wall Street’s top banks, JPMorgan, is calling for Broadcom shares to eclipse previous all-time highs by $100.
Should You Invest $1,000 in Broadcom Right Now?Before you consider Broadcom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Broadcom wasn't on the list.
While Broadcom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Strategy spustila nový rámec Digital Credit Capital Framework včetně zpětného odkupu digitálních cenných papírů a kmenových akcií až za 1 mld. USD a může pro něj prodat bitcoin až za 1,25 mld. USD.
Strategy shares are climbing with conviction. What’s driving MSTR stock higher? The Digital Credit Capital Framework has five components: a Board-approved USD Reserve policy, a revised STRC dividend policy, a Digital Credit Securities repurchase program of up to $1 billion, a class A common stock repurchase program of up to $1 billion, and a BTC Monetization Program. The announcement marks a meaningful strategic evolution, from one-way capital issuance toward active, two-way capital management.
The USD ReserveThe STRC Dividend and Repurchase ProgramsStrategy raised the dividend rate on its Variable Rate Series A Perpetual Stretch Preferred Stock to 12.00% annually, effective for semi-monthly periods with record dates on or after July 1, 2026. The company said its corporate objective is for STRC to trade near its $100 stated amount over time.
On the repurchase side, Strategy established a $1 billion program covering its Digital Credit Securities, including STRC, STRF, STRD, and STRK, with STRC expected to be the initial priority. A separate $1 billion class A common stock repurchase program was also announced.
The BTC Monetization ProgramThe Board authorized Strategy to sell Bitcoin for three primary purposes: to generate up to $1.25 billion to fund the USD Reserve, to fund preferred stock dividends and interest expense when management determines it is more advantageous than issuing equity, and to fund repurchases of Digital Credit Securities or common stock. Any BTC monetization outside these purposes requires additional Board authorization.
“Bitcoin is capital,” said Andrew Kang, CFO. “This program gives Strategy the flexibility to use a portion of its BTC Reserve to strengthen Digital Credit, fund dividend payments and interest expense, and fund accretive repurchases when BTC monetization is more advantageous than issuing common equity.”
Strategy Shares Trade HigherMSTR Price Action: At the time of publication, Strategy shares are trading 4.04% higher at $85.63, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Rocket Lab (NASDAQ: RKLB) stock price has suffered a major reversal in the past few weeks, moving from the year-to-date high of $151 on May 27 to $84. This retreat continued even after the company landed a new NASA contract last week. So, is it safe to buy the dip or sell the rip?
RKLB share price has dropped sharply in the past few weeks as investors booked profits following its spectacular rally ahead of the SpaceX IPO. It jumped to a record high of $151, up by 3,700% from its lowest level in 2014, with its market capitalization peaking at $82 billion.
The ongoing Rocket Lab stock retreat has coincided with that of other companies in the space industry. SpaceX itself has plunged by over 30% from its highest point after its IPO. Also, other top players in the space industry, like Planet Labs and Intuitive Machines, have also plunged recently.
The sell-off intensified recently after the company entered the blue-chip index, a move that forced ETF and mutual fund operators to buy it. It is common for stocks to pop after an ETF inclusion news and then retreat when it eventually happens.
Most importantly, demand for Rocket Labs’ solutions jumped after NASA selected the company for the Polarized Submillimeter Ice-cloud Radiometer (PolSIR) and Total and Spectral Solar Irradiance Sensor-2 (TSIS-2) missions. The deal is worth $300 million.
Rocket Lab’s growth is continuing, but valuation risks remainThe most recent financial results showed that Rocket Labs’ business is firing on all cylinders with the number of launches continuing growing. It made a record $200 million revenue, up by 63.5% from the same period last year. Also, the company’s revenue backlog surged to over $2.2 billion or 70+ missions.
While most of these orders are for its Electron product, the company is seeing more demand for its HASTE and Neutron projects. It secured 5 Neutron launches in the last quarter, with the manifest filling to end of the decade.
Analysts predict that Rocket Lab’s revenue growth will continue in the foreseeable future. The annual revenue is expected to be $915 million, up by 52% YoY. It is expected to grow by 41% next year to $1.29 billion.
Still, there are concerns about the company’s valuation, which has become extremely stretched in the past few months. It now trades with a forward price-to-sales ratio of 53, which is a massive number. This means that it will need to continue growing its revenues and boosting its profit metrics in the long term.
READ MORE: Here’s why Rocket Lab stock is ripe for a strong comeback
Rocket Lab stock chart | Source: TradingView
The daily chart shows that the RKLB share price has dived in the past few months, moving from a high of $151 to $84 today. Its current price is notable as it coincides with the ascending trendline that connects the lowest swings since November last year.
The stock remains above the 200-day Exponential Moving Average (EMA), a sign that all hope is not lost. It has also settled along the Strong, Pivot, Reverse level of the Murrey Math Lines tool.
Therefore, there is a likelihood that the Rocket Lab stock price will bounce back and retest the Major S&R level of $100 as investors buy the dip. This view will become invalid if the stock drops below the Strong, Pivot, Reverse level of the Murrey Math Lines at $75.
Rocket Lab oznámil navrženou akvizici Iridium za 8 miliard USD, čímž rozšíří byznys o satelitní komunikaci a opakované příjmy. Firma si zároveň zajistila bridge loan ve výši 3,6 miliardy USD.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The commercial space industry is entering a new phase. Simply reaching orbit is no longer enough to build a durable business. The companies likely to create the most shareholder value over the next decade are those that control more of the space economy — from designing satellites and launching them to operating the communications networks those satellites power.
SpaceX (NASDAQ:SPCX) demonstrated the power of that strategy with Falcon and Starlink. Now Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) has taken a major step in the same direction, announcing an acquisition that could reshape its business for years to come.
Rocket Lab Is Buying More Than a Satellite Company Rocket Lab announced it will acquire Iridium Communications (NASDAQ:IRDM) in an $8 billion cash-and-stock transaction expected to close in mid-2027. Iridium shareholders will receive $27 in cash plus Rocket Lab shares for each Iridium share they own.
Funding such a large transaction naturally raises monetary questions, and Rocket Lab also announced it secured a $3.6 billion bridge loan, giving it the financing needed to complete the acquisition while arranging longer-term capital.
The acquisition will create one of the few publicly traded companies spanning launch services, satellite manufacturing, spacecraft components, and global satellite communications.
That changes Rocket Lab’s economic model. Instead of relying primarily on one-time launch contracts, it gains a business built around subscription-like connectivity services for commercial customers, governments, maritime operators, aviation, and direct-to-device applications.
The acquisition also creates operational advantages as Neutron enters service. Rocket Lab would be positioned to launch future generations of Iridium satellites using its own rocket rather than purchasing launch services from outside providers. Keeping those launches in-house lowers expenses across the satellite replacement cycle while giving Rocket Lab greater control over scheduling and deployment.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
That mirrors the strategy that has helped SpaceX widen its competitive lead. Combining launch capability with ownership of the communications network allows a company to manage costs across the entire value chain instead of paying outside providers at every stage.
The Space Economy Is Becoming a Platform Business The competitive landscape is also changing. Some companies will specialize in building spacecraft or selling launch services. Others will own integrated platforms that design satellites, manufacture them, launch them, operate the network, and collect recurring service revenue long after the rockets leave the launch pad.
Iridium fills an important gap in Rocket Lab’s business. It brings a mature global communications network, licensed spectrum, long-term government relationships, and recurring cash flow that continues long after a satellite reaches orbit.
Granted, integrating an $8 billion acquisition carries execution risk. Rocket Lab must successfully close the transaction, integrate operations, manage its financing, and bring Neutron into commercial service on schedule. Those are meaningful challenges for any company.
Still, the strategic direction is becoming much clearer.
Key Takeaway In short, Rocket Lab is evolving from a launch company into a full-service space infrastructure platform. The proposed $8 billion acquisition of Iridium gives it communications networks, recurring revenue, licensed spectrum, and deeper government relationships, while Neutron has the potential to lower future deployment costs by bringing launches in-house.
SpaceX showed that controlling both transportation to orbit and the services delivered from orbit creates lasting competitive advantages. If Rocket Lab executes on this strategy, shareholders may eventually view this acquisition not as an expansion of its launch business but as the moment it transformed into an integrated space platform capable of competing across the entire space economy.
If You'd Bought Amazon When the Motley Fool Said To…In September 2002, Stock Advisor told subscribers to buy Amazon. In December 2004, Netflix. In April 2005, Nvidia. The newsletter still publishes two new stock picks every month — and over 23 years, has more than quadrupled the S&P 500. Here's how to get this month's picks:
- Join Stock Advisor for one year, with a 30-day money-back guarantee
- Get this month's two new picks — plus the Top 10 Rankings and the full historical pick list
- Read the analysis, decide for yourself, and trade through your own brokerage
Five years from now, you'll probably wish you'd bought this month's picks. Don't miss them.
Gladstone Investment uzavřela definitivní dohodu o koupi společnosti Extrude Hone, dodavatele přesných povrchových úprav pro letectví, automobilový průmysl, energetiku a další náročná odvětví.
MCLEAN, VA / ACCESS Newswire / June 29, 2026 / Gladstone Investment Corporation (NASDAQ:GAIN) ("Gladstone Investment") announced today that it has entered into a definitive agreement to acquire Extrude Hone, an Irwin, Pennsylvania-based company. Extrude Hone is a leading provider of precision surface-finishing solutions used in mission-critical applications such as aerospace, automotive, heavy industrial, energy and other demanding end markets. The company's proprietary technologies and service capabilities help customers improve product performance, reliability and manufacturing efficiency.
Extrude Hone represents another example of Gladstone Investment's focus on partnering with established lower middle market businesses that hold leading positions in specialized industrial niches. Extrude Hone has built a strong reputation for technical expertise, long-standing customer relationships and mission-critical manufacturing solutions across a diverse set of end markets.
"We are excited to partner with the Extrude Hone management team and support the company's next phase of growth," said Christopher Lee, Executive Vice President of Gladstone Investment. "Extrude Hone has developed a strong market position, differentiated capabilities and a long history of serving customers with highly engineered finishing solutions. We look forward to investing alongside management to build upon that foundation."
"This definitive agreement to acquire Extrude Hone positions us to close on the acquisition subject to a final approval by regulatory authorities. We are pleased that the acquisition will add another quality company to Gladstone Investment's portfolio of operating businesses. We expect it to produce both income for dividends to shareholders and longer-term appreciation for capital gains," said David Dullum, Chief Executive Officer and President of Gladstone Investment.
Gladstone Investment is a publicly traded business development company that seeks to make equity and secured debt investments in lower middle market businesses in the United States in connection with acquisitions, changes in control and recapitalizations. Additional information on the transaction can be found at www.gladstoneinvestment.com.
For Investor Relations inquiries related to any of the monthly dividend paying Gladstone funds, please visit www.gladstone.com.
Forward-looking Statements:
The statements in this press release regarding the longer-term prospects of Gladstone Investment, Extrude Hone, and their management teams, and the ability of Gladstone Investment and Extrude Hone to grow and expand are "forward-looking statements." These forward-looking statements inherently involve certain risks and uncertainties in predicting future results and conditions. Although these statements are based on Gladstone Investment's current plans that are believed to be reasonable as of the date of this press release, a number of factors could cause actual results and conditions to differ materially from these forward-looking statements, including those factors described from time to time in Gladstone Investment's filings with the Securities and Exchange Commission. Gladstone Investment undertakes no obligation to update or revise these forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
For further information: Gladstone Investment Corporation, (703) 287-5893
June 29, 2026 08:00 ET | Source: 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.
“Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital further increases our financial strength, providing the Company with strategic and operational flexibility,” said Kristian Humer, Chief Financial Officer of 4DMT. “The credit facility diversifies our capital structure, allowing us to focus on sustaining our execution momentum, growth planning across our innovative gene therapy pipeline and early commercial planning for 4D-150.”
“Hercules Capital is pleased to support 4DMT with a flexible financing solution as the Company advances 4D-150 through Phase 3 development and pre-commercial planning in wet AMD and DME,” said Lake McGuire, Managing Director at Hercules Capital, Inc. “This partnership reflects our commitment to backing innovative genetic medicines with the potential to transform treatment paradigms for patients with serious unmet needs.”
Under the terms of the agreement, 4DMT drew an initial $20 million at closing. An additional $30 million is available, at the Company’s option, through June 15, 2027, with an additional $100 million available upon the Company’s achievement of certain milestones, and the remaining $50 million available subject to final lender approval.
The Company’s cash, cash equivalents and marketable securities were $458 million as of March 31, 2026.
Leerink Partners served as the exclusive financial advisor to 4DMT on the strategic credit facility.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and expressed statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for, the clinical development of the Company’s product candidates; the Company's expectations regarding financing alternatives and its anticipated cash runway; the availability of, and the Company’s ability to access or draw, additional capital under the credit facility; the achievement of the milestones, conditions or approvals required to access such additional capital; the expected non-dilutive nature and benefits of the credit facility; and the Company’s financial, strategic and operational flexibility. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as may be required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Copart oznámil změnu ve vedení: Jeff Liaw odstoupí z funkce CEO a ředitele, od 31. července 2026 ho nahradí Jay Adair. Liaw zůstane jako zvláštní poradce.
DALLAS--(BUSINESS WIRE)--Copart, Inc. (NASDAQ: CPRT) today announced that Jeff Liaw will step down as Chief Executive Officer and director, effective July 31, 2026. The Board has appointed Executive Chairman Jay Adair — who previously led Copart as CEO — to resume the role of Chief Executive Officer effective July 31, 2026. Mr. Liaw will support the transition as Special Advisor to Mr. Adair.
“Jeff has provided Copart with extraordinary leadership over the past decade — first as CFO, then President, and finally as our third-ever CEO,” said Mr. Adair. “Under his stewardship the Company achieved all-time high transaction values, average selling prices, and auction liquidity. As a result, we are the trusted platform for insurance and commercial consignors all over the world. On behalf of everyone at Copart, I thank Jeff and wish him well.”
Liaw said, "Leading Copart has been the privilege of a professional lifetime. I'm grateful to the Company for affording me the opportunity, for the customers who have entrusted us with their business, and for my teammates all over the world whose tireless efforts enable us to serve our customers and members so well. I wish Copart and Jay the very best in the next chapter ahead and look forward to contributing to the Company's future success."
About Copart
Copart, Inc., founded in 1982, is a global leader in online vehicle auctions. Copart’s innovative technology and online auction platforms connect vehicle consignors to approximately 1 million members in over 185 countries. Copart offers a comprehensive suite of vehicle remarketing services to insurance companies, financial institutions, dealers, rental car companies, charities, fleet operators, and individuals, and offers vehicles via auction to dealers, dismantlers, rebuilders, exporters, and the general public. With operations at over 250 locations in 11 countries, Copart sold more than 4 million units in the last year. Copart currently operates in the United States (Copart.com), Canada (Copart.ca), the United Kingdom (Copart.co.uk), Brazil (Copart.com.br), the Republic of Ireland (Copart.ie), Germany (Copart.de), Finland (Copart.fi), the United Arab Emirates, Oman and Bahrain (Copartmea.com), and Spain (Copart.es). For more information, or to become a Member, visit Copart.com/register.
Cautionary Note About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are subject to substantial risks and uncertainties. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected or implied by our statements and comments. For a more complete discussion of the risks that could affect our business, please review the “Management’s Discussion and Analysis” and the other risks identified in Copart’s latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, as filed with the Securities and Exchange Commission. We encourage investors to review these disclosures carefully. We do not undertake to update any forward-looking statement that may be made from time to time on our behalf.
GE HealthCare spouští modernizační aktualizaci pro vybrané starší systémy Innova a Discovery IGS, která přidává technologie platformy Allia bez nutnosti velkých stavebních úprav. Program má zlepšit workflow, obrazovou kvalitu a snížit prostoje.
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations.
As procedural complexity and patient volumes grow and installed systems age, healthcare providers are looking for flexible ways to modernize interventional environments while balancing operational, infrastructure and capital planning priorities. According to the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), one-third of interventional X-ray systems in Europe are more than 10 years old, highlighting the importance of technology renewal planning to support increased access to advanced care.i
The upgrade pathways can help customers extend the value of existing systems through workflow enhancements, expanded interoperability capabilities and access to Allia innovations, while helping reduce infrastructure replacement needs and support long-term operational and sustainability goals.
“Interventional care continues to evolve rapidly, and health systems are looking for technology strategies that balance innovation, operational continuity and long-term value,” said Jyoti Gera, CEO, CardioVascular and Interventional Solutions, Advanced Imaging Solutions, GE HealthCare. “These Allia upgrade pathways reflect our commitment to helping customers modernize on their own terms by extending the capabilities of existing systems while providing access to the latest Allia innovations and AI-enabled technologies in a less disruptive, more sustainable way.”
Depending on system configuration, market availability and applicable regulatory requirements, upgrade options may provide access to capabilities and to third party solutions, including:
CleaRecon DL,ii an AI-enabled deep learning reconstruction technology designed to support CBCT image interpretation confidence by reducing streak artifacts caused by the pulsatile nature of blood flow during procedures. 3DStent,iii an intraprocedural tool for 3D visualization of the coronary stent designed to remove major stent imaging barriers and provide easy to interpret images. OmnifyXR™ Interventional Suite, an augmented reality guidance solution designed to support workflow efficiency and ergonomics and provide improved visualization and collaborative care for procedures such as prostate embolization.iv Embo ASSIST AI, an augmented guidance solution designed to optimize embolization strategies and streamline clinical workflow.v Medis Quantitative Flow Ratio®vi, a software solution, designed to assess coronary physiology in patients with coronary artery disease. AVVIGO™+ intravascular imaging (IVUS) platformvii multimodality guidance platform that enhances the IVUS and physiology experience and integrates percutaneous coronary intervention tools to support users in the catheterization lab. GE HealthCare also provides Tube Watch and/or OnWatch™ Predict service options on all upgraded systems. These options help customers proactively manage system performance and maintenance by providing an AI-poweredviii estimated lead time to failure, supporting efforts to reduce unplanned downtime.
These upgrade pathways are available in the U.S. and other countries where Allia IGS and Allia IGS Pulse systems are available for sale (and have been approved, cleared or registered by the appropriate regulatory authorities). Please contact your local GE HealthCare representative with any questions about this upgrade program. For more information on the available Allia upgrade capabilities, visit: https://www.gehealthcare.com/en-us/services/igs-upgrades.
Through GE HealthCare’s upgrade programs, customers can access technology designed to help enhance image quality, expand imaging capabilities with advanced applications, and streamline workflows across image guiding solutions, X-ray, MR and CT systems. These programs are designed to help customers unlock new value from existing systems through smart technology and AI-powered and digital solutions, while supporting productivity, operational continuity and patient-centered care.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
i COCIR. 2023. Medical Imaging Equipment Age Profile and Density: 2023 Edition.
https://www.cocir.org/wp-content/uploads/23060_COC_X-Ray-INTERVENTIONAL-scaled.jpg.
ii CleaRecon DL, designed to be used with Allia systems, is an option in 3DXR designed to be used with Allia systems and requires AW workstation with Volume Viewer. May not be available in all countries.
iii 3DStent solution includes Allia™ system, 3DXR and Volume Viewer Innova, and requires AW workstation with Volume Viewer. These applications are sold separately. Not available for sale in all countries. 3DStent is available on Allia™ IGS 5 with 20-cm or 30-cm detector and Allia™ IGS 7 with 30-cm detector.
iv OmnifyXR™ Augmented Reality Interventional Suite is a MediView product built in collaboration with and currently exclusively available with compatible GE HealthCare systems. OmnifyXR™ is intended to be used adjunctively to standard of care imaging. Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR™ system. OmnifyXR™ is not intended to be the sole visualization for any procedure.
v Embo ASSIST AI solution includes FlightPlan for Embolization with AI Segmentation option and requires AW workstation with Volume Viewer, Volume Viewer Innova, Vision 2, VesselIQ Xpress, Autobone Xpress. These applications are sold separately.
vi Medis QFR® is a product from Medis Medical Imaging.
vii AVVIGO+ is an option of Allia IGS 3, Allia IGS 5, Allia IGS 7, Allia IGS 7 OR. AVVIGO™+ is a trademark of Boston Scientific. AVVIGO™+ is manufactured and sold by Boston Scientific and is distributed by GE HealthCare. Refer to your Boston Scientific sales representatives for more information.
viii An AI-powered deep machine learning model trained on data from installed systems, leveraging aggregated error logs, parametric data, and historical service activity on eligible systems.
Tenable One Cloud Exposure získal autorizaci FedRAMP High a IL5, což rozšiřuje jeho využití v citlivých federálních prostředích včetně Ministerstva obrany USA a zpravodajských agentur.
COLUMBIA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Tenable® Holdings, Inc. (NASDAQ: TENB), the exposure management company, today announced that Tenable One Cloud Exposure has achieved FedRAMP® High and Impact Level (IL) 5 authorization, one of the U.S. government’s most stringent security certifications. Part of the Tenable One Exposure Management Platform, Tenable One Cloud Exposure is an actionable cloud security solution that provides unified visibility and AI-powered contextual insights to help organizations proactively identify and close critical exposure gaps across the entire cloud lifecycle.
The milestone significantly expands Tenable’s opportunities to support highly sensitive federal environments, including those used by the Department of War (DoW) and intelligence agencies. This new authorization builds on Tenable FedRAMP Moderate authorizations for both Tenable One Cloud Exposure and Tenable One, further cementing its role as a long-standing and trusted partner in the public sector.
As federal agencies accelerate cloud modernization and AI adoption, they face an increasingly complex landscape of misconfigured workloads, fragmented security tools and new attack vectors. Tenable One Cloud Exposure consolidates critical cloud security functions, previously spread across multiple tools, into a single, cost-efficient solution. By leveraging advanced identity analytics, Tenable enforces Zero Trust principles that align with DoW CIO mandates to ensure mission-critical resilience, cyber readiness and operational effectiveness.
This authorization also enables Tenable to support new mission-critical use cases, including classified and tactical edge deployments, and offers a clear competitive advantage in the federal space. Purpose-built for sensitive government cloud environments, Tenable One Cloud Exposure is a comprehensive Cloud Native Application Protection Platform (CNAPP) that delivers:
Unified visibility across infrastructure, identities and workloadsProactive identity risk management and enforcement of least privilegeContinuous compliance with evolving federal cybersecurity standards
“Achieving FedRAMP High authorization is a powerful validation of our public sector commitment and our ability to protect the most sensitive cloud workloads,” said Bob Huber, Chief Security Officer and President of Tenable Public Sector, LLC. “We’re proud to provide federal agencies with a unified exposure management platform that meets their toughest challenges: reducing risk, maintaining compliance and securely adopting AI with confidence.”
Tenable One Cloud Exposure received FedRAMP high authorization through UberEther’s AIM Advantage platform.
More information on Tenable One Cloud Exposure FedRAMP High is available at: https://www.tenable.com/solutions/government/us-fed
About Tenable
Tenable® is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. The company’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for more than 40,000 customers around the globe. Learn more at https://www.tenable.com.
Winnebago Industries NYSE: WGO reported earnings on June 25, and the results showed a company dealing with a consumer who is under pressure. The company missed on its top and bottom lines and lowered its full-year guidance. Still, WGO ended the day up 14.4% on a day when the broader market was struggling to find direction.
Winnebago Industries Today
WGO
Winnebago Industries
$31.24 -0.12 (-0.37%)
As of 06/26/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$26.80▼
$50.16Dividend Yield4.48%
P/E Ratio22.97
Price Target$37.22
The company’s quarterly report could be neatly summarized in the first minute of the conference call.
Get Winnebago Industries alerts:
At that point, president and chief executive officer (CEO), Michael Happe, remarked: “Our fiscal third quarter results reflect a demand environment that remains challenged with limited near-term visibility to stable conditions.”
That sentiment was echoed in the company’s earnings presentation, which featured a slide titled “Managing the Controllables.” Highlighting these statements is not meant to be dismissive of the company.
Rather, those statements revealed the blunt reality facing the company, which investors must understand to put the outlook for WGO in context.
Analysts and Industry Data Foreshadowed a Tough QuarterThe company’s weak Q3 2026 earnings report was foreshadowed by analysts who lowered their price targets ahead of the report. On June 23, Roth Mkm and Benchmark both lowered their targets for WGO to $32 and $40 from $38 and $48.
That goes along with the summer 2026 forecast from the RV Industry Association, which revised its forecast for shipped units to a range of 300,000 to 328,100 with a median of 314,000 units. At the median, that marks an 8.2% year over year decline.
Winnebago’s report aligned with that outlook. The company delivered revenue of $698.70 million, below estimates of $755.68 million. Adjusted earnings per share (EPS) of 66 cents were also below the estimates of 81 cents. Making matters worse, those numbers were down approximately 10% and 18% year-over-year, respectively.
Some context softens the blow. The company's gross margin came in at 13.6%, essentially flat with the 13.7% reported in the year-ago quarter. That suggests Winnebago is preserving pricing discipline even as volume contracts. On a GAAP basis, net income was $14.5 million, or 51 cents per diluted share. That's still a profitable quarter in what management plainly called a challenged demand environment.
A Different Consumer Meets a Different WinnebagoThe recreational vehicle (RV) industry thrived in 2020 and 2021. Consumers looking to travel but remain socially distant leaned hard into the outdoor lifestyle, including RVs. The benefit of low interest rates to accommodate financing and stimulus money flowing caused a boom for many RV makers, including Winnebago.
But those days are a distant memory. The macroeconomic picture is inverted, and the industry is faced with more “choiceful” consumers. The interest is still there; the commitment is lacking.
That fits into the bucket of things Winnebago can’t control.
However, while the state of the consumer is different, so is Winnebago. WGO trades right around where it was in 2019. But since the end of its 2019 fiscal year, the company acquired Newmar. Then, in 2021, it added Barletta Boats. More recently, the company acquired the Grand Design motorhome brand. That’s given the company several new revenue streams, and the company’s report makes it clear that the Newmar and Grand Design brands were bullish outliers in an otherwise poor quarter.
But that’s not showing up in the numbers. Winnebago made downward revisions to its full-year guidance. The company now expects revenue between $2.65 billion and $2.75 billion and adjusted EPS of $1.65 to $2.. Those don’t suggest growth, but if they are a worst-case scenario, it could explain the post-earnings price action
The WGO Chart Hints at a Short-Term SetupThe setup on the chart is worth a closer look. WGO gapped higher on Thursday to close at $30.87 on volume of 1.4 million shares. The move reclaimed the 50-day simple moving average (SMA) at $30.18 in a single session, flipping a key short-term resistance level into support.
The pattern rhymes with a setup from late summer 2025. Back then, the stock built a multi-week base near $28 to $30 before breaking out and spiking through the fall. WGO has spent the last two months consolidating in that same price zone, and Thursday's surge on outsized volume could mark the start of a similar leg higher.
Momentum indicators are starting to confirm. The moving average convergence divergence (MACD) line has crossed above its signal line, and the histogram has flipped positive. That's an early bullish trigger, though it needs follow-through to carry weight.
Resistance sits in the $36 to $38 zone, where the stock topped last fall, and again near $44, where buyers stalled in February. A failure to hold the $28 level would invalidate the setup. For investors who can stomach the cyclical risk, the current reaction offers a defined-risk entry into a name already trading at depressed multiples.
Should You Invest $1,000 in Winnebago Industries Right Now?Before you consider Winnebago Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Winnebago Industries wasn't on the list.
While Winnebago Industries currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Darden Restaurants' NYSE: DRI stock price is on track to hit new highs because its high-quality business is outperforming peers, growing across brands, generating ample cash flows, and sustaining a robust capital return program. The capital return program is a significant factor in 2026, with investors reducing exposure to high-risk tech stocks in favor of safer havens. For Darden Investors, that means a reliable dividend with market-beating yield and aggressive share buybacks.
Darden Restaurants Today
DRI
Darden Restaurants
$213.79 +0.07 (+0.03%)
As of 06/26/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$169.00▼
$222.56Dividend Yield2.81%
P/E Ratio20.60
Price Target$228.32
Dividends yield 2.8% with shares trading near record highs. The record highs are another significant factor in 2026, as DRI’s price action has been winding up within a range for the past 18 months. Assuming a break to new highs, the technical setup suggests a $60 upside from the critical resistance level, potentially reached within months. Triggers for the market include expected dividend increases, which have been growing at a double-digit annual rate, and buybacks.
Get Darden Restaurants alerts:
Darden’s management expressed high confidence in future cash flows by increasing its buyback allotment. The fiscal-year authorization of $1.5 billion represents more than 6% of the late-June market, keeping the company on track to sustain its aggressive pace. As it stands, the fiscal year 2026 (FY2026) activity reduced the count by an average of 1.7% for the year and by 2.2% for Q4 FY2026.
Darden Gobbles Up the Competition in Fiscal Q4Darden Restaurants had a solid quarter with revenue growing by 13.7% to $3.72 billion. Earnings results were strong, even accounting for an extra week in the quarter. Comps were up by 4.6% across the network. Longhorn Steakhouse led, growing by 9.5%, followed by a 4.6% increase in Other, a 2.4% increase at Olive Garden, and a 1.9% increase at Fine Dining establishments. New stores accounted for 2% of the growth.
Margin news was also good. The company managed to control costs and drive improved bottom-line results. Adjusted earnings grew by an accelerated 22.8%, nearly doubling the top-line advance, and outpaced the consensus despite a slim miss in revenue. Looking ahead, earnings strength is expected to continue, as reflected in the guidance. The only bad news is that the earnings-per-share mid-point of $11.225 was below the consensus estimate, which could produce a headwind for near-term price action.
Analysts and Institutions Support Darden Restaurants Stock in 2026Analysts' bullish trends provide support for the market. MarketBeat tracks 27 who rate the stock as a consensus Moderate Buy with 63% Buy-side bias in the data. The consensus price target assumes fair value near the current all-time high, but recent revisions are pushing the upper end of the range. Bank of America set a high target in early June of $276, well above the existing high and nearly a 30% gain from the pre-release close.
Overall MarketRank™76th Percentile
Analyst RatingModerate Buy
Upside/Downside6.8% Upside
Short Interest LevelBearish
Dividend StrengthModerate
News Sentiment0.62 Insider TradingSelling Shares
Proj. Earnings Growth9.56%
See Full Analysis
Institutional activity also reflects support and a high potential for this group to buy DRI shares upon price weakness. They own about 94% of the stock and have been aggressively accumulating at a $2-to-$1 pace over the trailing 12 months. Their activity ramped up in late 2025 and early 2026 as price action pulled back from near-record highs, and will likely do so again when a discount presents itself. Short interest is mildly elevated at nearly 5%, but not a problem at this time, more likely tied to hedging activity than bearish trading.
Darden’s stock price fell about 3% in premarket trading following earnings release, before recovering partially after the open. Long-term, the decline could extend further. The caveat is that this market pulled back to a congestion zone where buyers are likely waiting.
The more likely scenario is that the DRI price stock bottoms quickly, confirming support in the $190 to $200 range by summer’s end, while the less likely scenario is that price action falls significantly further. The critical support target is $190; a move below it could trigger a fall to $175 or lower.
Darden’s biggest risks this year are consumer trends and commodity prices. Consumer trends are sluggish, impaired by inflationary pressures, but not yet reflected in DRI results. Commodity pricing, specifically beef, is a more pressing issue impairing restaurant-level margins. The company’s solution is to increase prices slowly, trailing inflation, to keep consumers coming back while mitigating cost increases.
Other offsets include operational efficiencies, scaling purchase agreements across brands, and hedging activities in anticipation of future price changes. Catalysts include the integration and scaling of its acquisitions, the conversion of Bahama Breeze to new formats, and the expansion of its footprint. The 2027 guidance includes plans for up to 80 new stores, a 3.6% increase relative to 2026’s final count.
Should You Invest $1,000 in Darden Restaurants Right Now?Before you consider Darden Restaurants, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Darden Restaurants wasn't on the list.
While Darden Restaurants currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Martin Marietta Materials se spojí s Lhoist North America v transakci za 13,5 miliardy USD, financované 7 miliardami USD v hotovosti a akciemi za 6,5 miliardy USD.
A specialist trader works at the post where Martin Marietta Materials is traded on the floor of the New York Stock Exchange (NYSE) in New York, U.S., March 6, 2017. REUTERS/Brendan McDermid Purchase Licensing Rights, opens new tab
SummaryCompaniesMartin Marietta to fund the deal with $7 billion cash and $6.5 billion in sharesThe Berghmans family would own roughly 15% of Martin Marietta after deal closesThe transaction would add 2 billion tons of limestone reserves in Sun Belt corridorsJune 29 (Reuters) - Martin Marietta Materials (MLM.N), opens new tab said on Monday it would merge with limestone supplier Lhoist North America in a cash-and-stock deal worth $13.5 billion, as the building material firm looks to tap growing demand for lime products.
Shares of the Raleigh, North Carolina-based company were down about 3% in premarket trade.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Martin Marietta will use a mix of $7 billion in cash along with shares valued at $6.5 billion to fund the deal, the company said. It expects to realize about $85 million in annual run-rate cost synergies.
Martin Marietta CEO Ward Nye said demand for high-quality lime products is expected to remain resilient for decades to come, due to investment in infrastructure, advanced manufacturing, energy development and industrial expansion in the U.S.
There has been a surge in dealmaking in the U.S. building-products industry as the data center construction business booms, along with new housing, repairs and renovations.
Last week, Ireland's CRH (CRH.N), opens new tab said it would acquire Arcosa (ACA.N), opens new tab in an all-cash deal valued at about $8.5 billion, in a bid to capitalize on rising demand for U.S. energy and utility infrastructure.
Lhoist's Berghmans family - which owns the privately held Lhoist Group, a Belgian industrial company - would own roughly 15% of Martin Marietta upon the deal's close.
The transaction would add quarries, production facilities, distribution terminals and 2 billion tons of limestone reserves in Sun Belt metropolitan corridors to Martin Marietta's portfolio.
Lhoist North America makes hi-calcium lime, dolomitic lime and industrial mineral products used in domestic steel manufacturing, infrastructure and heavy non-residential construction across North America.
The deal is expected to be completed in the second half of 2026, subject to regulatory approvals.
Reporting by Anshuman Tripathy in Bengaluru; Editing by Shailesh Kuber and Devika Syamnath
Our Standards: The Thomson Reuters Trust Principles., opens new tab
FactSet oznámil partnerství s TIFIN.AI a strategickou investici do firmy, aby urychlil nasazení AI workflow pro správu majetku. První nástroje mají zvyšovat produktivitu poradců a personalizaci služeb.
June 29, 2026 08:30 ET | Source: FactSet Research Systems Inc.
The partnership brings FactSet’s trusted financial intelligence directly into agentic advisor workflows, helping advisors deliver personalized service at scale
NORWALK, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- FactSet, a leading global data and AI solutions provider to the financial markets, today announced a partnership with TIFIN.AI, a leading AI platform for the wealth, asset management, and insurance industries, to accelerate the delivery of next-generation AI-powered workflows for wealth management firms. To further cement this long-term collaboration, FactSet has also made a strategic investment in TIFIN.AI, reflecting both companies’ commitment to accelerating the adoption of AI-powered workflows and advancing innovation across the wealth management sector.
Through the partnership with TIFIN.AI, FactSet will offer solutions to increase advisor productivity, deepen client engagement, and deliver personalized client service. FactSet’s clients will gain access to a growing suite of AI-powered capabilities integrated within FactSet Workstation and the broader wealth management ecosystem, with opportunities to expand across additional wealth management workflows over time. Initial solutions include:
Meeting Prep Agent: generates client-ready summaries, action items, portfolio insights, and personalized talking points in minutes, so advisors can focus less on prep and more on building meaningful client relationships.Book Intelligence Agent: surfaces actionable insights across an advisor’s book of business to help identify portfolio opportunities, strengthen client engagement, and prioritize outreach. The new suite features:
Institutional-Grade Intelligence: a combination of FactSet’s institutional-grade market data, analytics, and wealth management capabilities paired with TIFIN.AI’s purpose-built agentic workflow technology.Seamless Workflow Integration: the solution is designed to embed directly into advisor workflows, enabling firms to enhance productivity without disrupting existing operating models.Secure Enterprise-Ready Architecture: TIFIN.AI’s engine will operate entirely within FactSet’s infrastructure, ensuring client portfolio data remains inside FactSet’s environment.Auditable AI: the solution leverages FactSet's domain-specific answers engine and auditable workflows, providing firms with traceability into generated insights and helping mitigate hallucination risks associated with generic large language models. "This partnership reflects FactSet's continued commitment to helping wealth management firms modernize advisor workflows through practical, enterprise-grade AI solutions," said Kristina Karnovsky, Executive Vice President, Co-Head of Product at FactSet. "By combining FactSet's trusted data infrastructure and analytics capabilities with TIFIN's agentic workflow technology, we are enabling firms to deliver more personalized client experiences at scale while maintaining the transparency, governance, and operational rigor the industry requires. We are excited to continue building agents that drive innovation and efficiency for our wealth clients across critical workflows."
“FactSet’s strategic partnership reflects a shared belief that agentic workforces will play an important role in the future of wealth management,” said Harshendu Bindal, CEO of TIFIN.AI. “By combining FactSet’s trusted intelligence with our agentic capabilities, we are advancing a new generation of advisor workflows.”
Full details on FactSet’s AI solutions for wealth are available here: www.factset.com/marketplace/catalog/product/factset-ai-for-wealth.
About FactSet
FactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that power our clients to maximize their potential. Our cutting-edge digital platform seamlessly integrates proprietary financial data, client datasets, third-party sources, and flexible technology to deliver tailored solutions across the buy-side, sell-side, wealth management, private equity, and corporate sectors. With over 47 years of expertise, offices in 19 countries, and extensive multi-asset class coverage, we leverage advanced data connectivity alongside AI and next-generation tools to streamline workflows, drive productivity, and enable smarter, faster decision-making. Serving more than 9,000 global clients and over 241,000 individual users, FactSet is a member of the S&P 500 dedicated to innovation and long-term client success. Learn more at
www.factset.com and follow us on
X and
LinkedIn.
About TIFIN.AI
TIFIN.AI is an AI platform for wealth, asset management, and insurance. The company builds
agentic workforces to augment functions across wealth. Its systems connect data, software and
workflows, with the goal of delivering better wealth outcomes for more people.
FactSet Investor Relations:
Kevin Toomey
+1.212.209.5259 [email protected]
FactSet Media Relations:
Alexandra Shevchenko
+44 075 1813 1115 [email protected]
Saab podepsal s Polskem kontrakt za 47 miliard korun na tři ponorky A26. Součástí je i výzbroj, výcvik a podpora; dodávky mají být dokončeny v roce 2038.
The Saab Technologies logo is displayed during the fifth day of Dubai Air Show in Dubai, United Arab Emirates November 21, 2019. REUTERS/Christopher Pike/File Photo Purchase Licensing Rights, opens new tab
STOCKHOLM, June 29 (Reuters) - Sweden's Saab (SAABb.ST), opens new tab said on Monday it had signed a 47 billion crown ($4.83 billion) contract with Poland for three A26-type submarines.
Saab said in a statement the contract also includes a weapon package and a training and support package with final deliveries scheduled for 2038.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
Poland announced last year that it had chosen Saab to supply it with three submarines, in a multi-billion-dollar deal that forms a key element of Warsaw's efforts to bolster its defences in the Baltic Sea.
"Sweden and Poland have successfully concluded negotiations on Poland's acquisition of three A26 submarines from Saab," the Swedish government said in a separate statement.
"The agreement is a significant step in strengthening Poland's naval capabilities and at the same time contributes to Sweden and Poland deepening their security and industrial policy cooperation," it said.
($1 = 9.7251 Swedish crowns)
Reporting by Anna Ringstrom and Johan Ahlander, editing by Essi Lehto
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Booz Allen Hamilton oznámila partnerství s OpenAI pro rychlejší a bezpečnější nasazení AI pro obranné, zpravodajské i komerční operace. Dohoda má firmám přinést nové technické know-how, přehled o roadmapě, technickou podporu a školení.
Accelerating secure AI deployment for U.S. agencies and commercial enterprises
MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen Hamilton (NYSE: BAH) today announced a new partnership with OpenAI to promote advanced AI innovation across national security and critical infrastructure missions. With OpenAI, Booz Allen will share mission and model insights that enable faster, more secure deployment of AI solutions tailored to defense, intelligence, and commercial operations.
"Keeping pace with fast‑moving frontier models is mission‑critical for our customers... Our partnership gives agencies and enterprises the edge to move faster and drive AI adoption across the most complex operating environments." -Bryce Pippert, Booz Allen
Share“Keeping pace with fast-moving frontier models is mission-critical for our customers. They need the best AI ready for real-world operations. Our partnership gives agencies and enterprises the edge to move faster and drive AI adoption across the most complex operating environments,” said Bryce Pippert, executive vice president leading ventures and partnerships at Booz Allen.
The partnership creates a powerful feedback loop between model developers and frontline practitioners, enabling both organizations to move at the speed of technological change while delivering scalable AI that meets the highest standards for security, reliability, and impact.
“AI is only as strong as the environment it runs in. Our partnership with Booz Allen brings secure AI to the frontlines of national security missions and beyond,” said Joe Larson, vice president, OpenAI for Government.
The partnership expands on existing collaboration between the companies, giving Booz Allen engineers new access to OpenAI’s roadmap insights, technical enablement, and training resources. This builds on the multi-tier AI upskilling programs, digital badging, and Technical Experience Groups (TXGs) that connect Booz Allen’s top technical talent with emerging mission needs to accelerate secure AI deployment for customers.
About Booz Allen Hamilton
Booz Allen is an advanced technology company. We build commercial-grade products and solutions for America’s most critical defense, civil, and national security priorities. For more information, visit www.boozallen.com. (NYSE: BAH)
Nintendo dnes vyplatí první z letošních dvou dividend ve výši 177 JP¥ na akcii, tedy 17 700 JP¥ za 100 akcií. Oproti prosincové dividendě 42 JP¥ je to nárůst o 321,43 %.
Nintendo (TYO: 7974) is preparing to deliver the first of its two yearly dividends today, June 29, when shareholders are going to receive a dramatically larger payout than six months ago.
Notably, the company announced a payment of JP¥177 ($1.09) per share, meaning investors holding 100 Nintendo shares will receive JP¥17,700 ($109) in semiannual dividends, or P¥35,400 ($218) this year if the payout remains unchanged.
As such, today’s payout represents a 321.43% increase from Nintendo’s most recent dividend of JP¥42 ($0.26) per share paid in December 2025, according to DivvyDiary data.
Nintendo dividends calendar. Source: DivvyDiary To be eligible for the payout, shareholders must own Nintendo stock as of the March 30 ex-dividend date.
Note that for investors outside Japan, the company’s American Depositary Receipts (ADRs) trade on the U.S. over-the-counter (OTC) markets under the ticker NTDOY.
Nintendo dividend history The upcoming Nintendo stock dividend thus marks a sharp rebound from the company’s latest payment cycle.
Namely, in 2025, Nintendo paid a total annual dividend of JP¥127 ($0.78) per share, consisting of a JP¥85 ($0.52) payment in June and a significantly smaller JP¥42 ($0.26) payment in December, which represented a 50.59% decline.
Now, the June 29 JP¥177 ($1.09) dividend not only exceeds the December payout by more than four times but also stands JP¥92 ($0.57) higher than the company’s larger June 2025 distribution of JP¥85 ($0.52).
The increase comes as the gaming giant’s stock is down about 35% year-to-date. As a result, the substantial improvement in shareholder returns is seen by many as potentially reflecting stronger earnings expectations, capital allocation decisions, or improved business performance heading into fiscal 2026.
What’s more, the Japanese company also raised employee salaries by 10% just two days prior, and its shares were up roughly 5% on the daily chart at the time of writing, which has boosted confidence in management’s vision and the firm’s financial position.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Comstock Metals oznámila, že do závodu dorazilo a bylo smontováno veškeré zařízení pro průmyslovou linku na recyklaci solárních panelů. Tři jednotky už byly zprovozněny a otestovány, plný provoz má začít do konce července 2026.
VIRGINIA CITY, Nev., June 29, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) and Comstock Metals LLC (“Comstock Metals”), a leader in the responsible recycling of end-of-life solar panels with the only certified, North American, zero-landfill solution, announced today that all of the industry-scale facility precision equipment and unit operations have arrived and are assembled. Three of those unit operations have been commissioned and tested and are undergoing integration to date: the robotic loading arms, the Eddy system, and the washing system. This represents significant progress toward the full commissioning, start-up and continuous operation of the 100,000 ton per year solar panel recycling production line.
“We are pleased to report that, as of last week, we completed the “tuning” of the entire glass-upgrading Eddy system, including full capacity stress-testing. The unit met and exceeded its quality and capacity performance requirements operating at full capacity levels and working towards delivering clean glass that meets or exceeds all the quality specifications communicated from our customers,” stated Corrado De Gasperis, CEO of Comstock Inc.
“A production plant comes to life the way a finely tuned orchestra does. Each instrument is tuned individually to make sure it is working and if not, then retuned, and then stress-tested at volumes representing the equipment’s stated capacities, and only then does the true performance begin,” stated Dr. Fortunato Villamagna, Comstock Metals’ President. “Our plant is moving through that same sequence, and the instruments, the nine distinct unit operations that make up our process, are now being tuned one by one.”
“The start-up sequence is largely dictated by the engineering requirements and, in part, in response to requests for materials and samples from the growing population of our potential offtake customers,” continued Villamagna. “We are currently stress-testing the other two-unit operations that are now calibrated, while beginning the “tuning process” for the next three in the sequence.”
Commissioning, and all aspects of integration, tuning, and staged stress-testing will continue through late July 2026, when continuous operations will commence. The first full month of operation will begin within the next two months.
About Comstock Inc.
Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit www.comstock.inc.
Comstock Social Media Policy
Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222 [email protected]
For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573 [email protected]
Forward-Looking Statements
This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances and business combinations; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings of equity or debt securities; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company or any other issuer.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ace2c6ae-fe59-4dd6-b98f-a3619f25b23a
Vertical Aerospace uzavřela s Astronics dlouhodobou dohodu o dodávkách nízkonapěťového rozvodu pro eVTOL Valo. Systém je už integrován do letového testovacího prototypu.
LONDON & EAST AURORA, N.Y.--(BUSINESS WIRE)--Vertical Aerospace ("Vertical" or the "Company") (NYSE: EVTL), a global aerospace and technology company that is pioneering electric aviation, today announced a long-term agreement with Astronics Corporation (NASDAQ: ATRO), a leading provider of advanced technologies for the global aerospace, defense and other mission critical industries, to supply the low-voltage ("LV") power distribution system for Vertical's Valo electric vertical take-off and landing (eVTOL) aircraft.
Under the agreement, Astronics will provide the aircraft's LV power distribution system, including power conversion and distribution hardware that manages and protects electrical power for critical aircraft systems. The system converts high-voltage electrical power from the aircraft's propulsion architecture into low-voltage power used by avionics, flight controls and other essential onboard systems.
Astronics has supported Vertical throughout the prototype phase of aircraft development, with its hardware already integrated into Vertical's piloted flight test aircraft. The company's purpose-built eVTOL electrical power solutions and extensive aerospace experience make it the ideal supplier for Valo as Vertical advances toward certification and commercial production.
This agreement further strengthens Vertical's supplier ecosystem across Valo’s key aircraft systems, including leading suppliers such as Honeywell (flight control and aircraft management systems), Aciturri (airframe structures), Evolito (electric propulsion units), Hyundai WIA (landing gear), Syensqo (composite materials) and Isoclima (transparencies).
Stuart Simpson, CEO of Vertical Aerospace, said:
"Building a certifiable aircraft requires not only breakthrough technology, but also a world-class supplier ecosystem. Astronics brings deep expertise in aircraft electrical power systems and has already demonstrated its capabilities through our flight test programme. This agreement is another important step as we mature Valo's design, strengthen our supply chain and advance toward certification and commercial production."
Jon Neal, President of Astronics Advanced Electronic Systems, said:
"Astronics is proud to be working with Vertical Aerospace as the supplier of their power distribution system for the Valo aircraft. Our CorePower® system is purpose-built for eVTOL applications, combining high-voltage power conversion with low-voltage power distribution delivering reliable, fault-protected power to flight-critical systems including avionics, flight controls, and navigation. CorePower was designed from the ground up to meet aerospace certification standards, giving our customers a lightweight, compact solution that reduces integration risk and supports their path to type certification. We look forward to continuing our close collaboration with the Vertical team through CDR and Valo's entry into service.”
The announcement follows continued progress on the Valo programme as Vertical advances toward Critical Design Review (CDR), establishing the certifiable design baseline for the aircraft ahead of certification-conforming aircraft production and testing.
About Astronics Corporation
Astronics Corporation (Nasdaq: ATRO) serves the world’s aerospace, defense, and other mission critical industries with proven, innovative technology solutions. Astronics works side-by-side with customers, integrating its array of power, connectivity, lighting, structures, interiors, and test technologies to solve complex challenges. For over 50 years, Astronics has delivered creative, customer-focused solutions with exceptional responsiveness. Today, global airframe manufacturers, airlines, militaries, completion centers and Fortune 500 companies rely on the collaborative spirit and innovation of Astronics. The Company’s strategy is to increase its value by developing technologies and capabilities that provide innovative solutions to its targeted markets. For more information on Astronics and its solutions, visit Astronics.com.
About Vertical Aerospace
Vertical Aerospace is a global aerospace and technology company pioneering electric aviation. Vertical is creating a safer, cleaner, and quieter way to travel. Valo is a piloted, four-passenger, Electric Vertical Take-Off and Landing (eVTOL) aircraft, with zero operating emissions. Vertical is also developing a hybrid-electric variant, offering increased range and mission flexibility to meet the evolving needs of the advanced air mobility market.
Vertical combines partnerships with leading aerospace companies, including Honeywell, Syensqo and Aciturri, with its own proprietary battery and propeller technology to develop the world's most advanced and safest eVTOL.
Vertical has c.1,500 pre-orders of Valo, with customers across four continents, including American Airlines, Avolon, Bristow, GOL and Japan Airlines. Certain customer obligations are expected to be fulfilled via third-party agreements. Headquartered in Bristol, UK, Vertical's experienced leadership team comes from top-tier aerospace and automotive companies such as Rolls-Royce, Airbus, GM, and Leonardo. Together, they have previously certified and supported over 30 different civil and military aircraft and propulsion systems.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements as contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding a long-term supply agreement with Astronics to supply the low-voltage power distribution system for Valo, the design and manufacture of our aircraft and the hybrid-electric variant, certification and the commercialization of our aircraft and our ability to achieve regulatory certification of our aircraft product on any particular timeline or at all, the features and capabilities of the aircraft, business strategy and plans and objectives of management for future operations, including the building and testing of our prototype aircrafts on timelines projected, completion of the piloted test programme phases, selection of suppliers; as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate,” “will,” “aim,” “potential,” “continue,” “are likely to” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”) on March 24, 2026, as such factors may be updated from time to time in our other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today that it has been added as a member of the Russell 2000® and the Russell 3000® indexes, effective when the US market opens on June 29, as part of the first 2026 Russell indexes reconstitution.
The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for half a year beginning 2026, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 2000 and 3000 Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
“Our inclusion in the Russell 2000 and Russell 3000 indexes is a meaningful milestone for Perma-Pipe and a reflection of the progress we have made in growing the Company and creating value for our shareholders," said Saleh Sagr, President and Chief Executive Officer of Perma-Pipe. "Building on our record fiscal 2025 results, this recognition enhances our visibility within the investment community and supports our ongoing commitment to greater transparency and engagement with shareholders and investors as we continue to execute our global growth strategy."
Perma-Pipe International Holdings, Inc.
Perma-Pipe International Holdings, Inc. (the “Company”) is a global leader in pre-insulated piping and leak detection systems for oil and gas gathering, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, the Company has operations at fourteen locations in seven countries.
Forward-Looking Statements
Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) fluctuations in the price of oil and natural gas and its impact on customer order volume for the Company's products; (ii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (iii) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve sustained profitability and positive cash flows; (vi) the Company's ability to collect a long-term account receivable related to a project in the Middle East; (vii) the Company’s ability to interpret changes in tax regulations and legislation; (viii) the Company's ability to use its net operating loss carryforwards; (ix) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s "over-time" revenue recognition; (x) the Company’s failure to establish and maintain effective internal control over financial reporting; (xi) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (xii) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xiii) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xiv) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xv) reductions or cancellations of orders included in the Company’s backlog; (xvi) risks and uncertainties specific to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the impact of pandemics and other public health crises on the Company and its operations; and (xx) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com.)
More News From Perma-Pipe International Holdings, Inc.
SpaceX vydala dluhopisy za 25 miliard USD a poptávka byla obrovská, téměř 90 miliard USD v objednávkách. Emise ale vyvolala obavy z vysokých kapitálových výdajů a budoucího refinancování.
SpaceX's $25 billion foray into debt markets appeared to be well received by bond markets last week, with huge demand for the offering.
But one of the biggest-ever AI bond issuances, less than two weeks after SpaceX's IPO, has highlighted the group's intense financing needs, capital spending plans and future refinancing obligations — and posed a diversification challenge for investors.
Why SpaceX tapped debt marketsThe group tapped debt markets on June 22, announcing a senior unsecured notes offering, with sources telling CNBC that the company was looking to raise $20 billion, which was then increased to $25 billion. The company said it would use the net proceeds to "repay the outstanding borrowings under its bridge loan facility in full, to pay related fees and expenses, and any remaining amount for general corporate purposes."
SpaceX stock soared after its hotly-anticipated IPO. Last week's debt issuance dented investor confidence.
SpaceX received nearly $90 billion worth of orders, people familiar with the fundraising previously told CNBC. They asked not to be named because the details are private.
But the move appeared to unnerve equity investors, with SpaceX falling more than 13% for the week after a strong post-IPO run.
Chris Beauchamp, chief market analyst at IG, said SpaceX will increasingly have to "work hard to make itself heard," adding there are plenty of offerings from more profitable concerns that can steal the limelight.
"Equity investors are one thing, but bond guys are the grown-ups in the room," Beauchamp told CNBC via email. "SpaceX might find it has its work cut out for it, but I suspect the market can absorb the issuance overall."
"The timing certainly isn't great, but we have seen brief bouts of panic like this before, and the wagon tends to roll onwards in the end."
Christopher Della Fave, senior vice president, capital markets at Post Oak Group, said: "Two weeks after the largest IPO in history, SpaceX is already tapping debt markets while carrying a $5 billion net loss and capex that more than doubled year over year."
Why SpaceX bonds raise diversification questionsDella Fave said SpaceX's losses and high capital expenditure aren't "alarming" in isolation, as "capital-intensive growth companies run hot."
However, he highlighted "the structural issue" that "investors aren't pricing in."
"Owning SPCX equity and SpaceX bonds isn't diversification," Della Fave added. "It's the same execution risk across two instruments."
"Starlink has to scale. Starship has to work. Both the equity story and the debt service depend on it. For portfolio construction, we treat total SpaceX exposure as a single concentrated position regardless of instrument, the same way you'd approach any single-name technology bet dressed up as a multi-asset allocation."
SpaceX's multi-billion-dollar debt issuance means many investors have become exposed to the group via two different asset classes – equities, via its blockbuster IPO on June 12 – and now, corporate bonds.
"Nearly all investors already hold allocations to US technology and the purpose of bonds as an asset class is surely to diversify," Julian Howard, multi-asset head at Gam, told CNBC on Friday.
He pointed out that SpaceX's 10-year issue is trading at a relatively tight spread to the equivalent U.S. Treasury of 1.4 percentage points.
In the debt sale, SpaceX priced bonds in five different tranches, with notes due between 2031 and 2056. Rates vary from 5.35% for the 2031 bonds to 6.65% for the 2056 notes.
"While that is comfortably ahead of inflation, the risk will be that spreads will widen if there is any hint of SpaceX not meeting its ambitious revenue targets, or if the outlook for tech and AI falters in any way," he added.
In the long term, SpaceX faces two big challenges in the markets, said Morningstar chief investment officer Mike Coop.
"Firstly, the supply of shares will go up as early investors lighten up exposures and monetize gains," he told CNBC.
"Secondly, the current price is too high given the massive uncertainty around the company's prospects and its starting point of being heavily loss making and requiring huge capital investment."
SummaryCompaniesAntitrust case is Apple's biggest regulatory headache in IndiaApple asks for investigation findings to be quashedCompany says it is a 'minuscule player' in IndiaIndia watchdog probe found Apple engaged in 'abusive conduct'NEW DELHI, June 29 (Reuters) - Apple has accused Indian antitrust investigators of "copy-pasting" its rivals' claims and failing to properly conduct its own investigation in concluding the U.S. tech giant breached competition laws, calling for the findings to be quashed, regulatory papers reviewed by Reuters showed.
The June 25 Apple (AAPL.O), opens new tab submission, being reported for the first time, marks the sharpest escalation yet in Apple's fight with the Competition Commission of India (CCI), where Tinder-owner Match (MTCH.O), opens new tab and Indian startups are among its opponents.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
In 2024, CCI investigators privately issued a report saying Apple engaged in "abusive conduct" on the apps platform of its iOS operating system, and wrongly mandated the use of its payment system.
Apple has denied the allegations. It said in its submission that it was a "minuscule player" with an under 6% share of India's smartphone market, and the investigation conclusions were built on rivals' claims rather than on the CCI's independent analysis.
Apple said any "forced alterations to Apple's carefully designed App Store could disrupt its integrated business model," and argued against any penalties and behavioural remedies that could force it to change its approach.
"The imposition of remedies would create regulatory uncertainty and could deter investments in India's digital economy," the company added.
The CCI and its head of investigations did not respond to Reuters queries. Apple also did not respond to requests for comment.
Similar arguments by other big companies have failed to sway the CCI. In 2023, Alphabet's (GOOGL.O), opens new tab Google argued in its antitrust case that CCI's order risked stalling its growth, but the company was later forced to make changes to the way it promoted its Android system, which dominates the Indian smartphone market.
Senior officials from the CCI are due to hold a closed-door hearing with all parties in the case on July 21.
'COPY-PASTING' ALLEGATIONSIn its submission, Apple drew up tables to argue the CCI investigation team had not done its own analysis and instead indulged in "copy-pasting" many submissions from opponents in the case such as Match, Walmart's Indian payments app, PhonePe, and Indian rival Paytm.
"The DG (Director General) made no effort whatsoever to independently verify or critically assess these statements, often parroting them verbatim," Apple said.
Match, Paytm and PhonePe did not respond to Reuters requests for comment.
Apple also said the CCI investigation reports "blindly replicated" a graphic on worldwide consumer spending on mobile apps and games from an EU ruling against Apple in 2024, even though India faced different market conditions.
A Reuters review of footnotes of the EU order and Indian investigation report showed both referenced data from Statista, an online research website.
In 2023, Google also argued Indian investigators copied parts of a European ruling. "We have not cut, copy and pasted," CCI said at the time.
WATCHDOG SAYS APPLE STALLING CASEApple is facing antitrust challenges around the world, from Europe to the United States.
The Indian case, however, is progressing at a time when Apple faces many supply chain issues, including a data breach at its Indian contract manufacturer Tata.
The watchdog has accused Apple of stalling the case for more than two years by not submitting responses to the investigation findings and pursuing a parallel challenge to India's antitrust penalty law, which allows for potential fines of up to 10% of company turnover in the previous three years. The CCI has not said which Apple revenues might be considered but any fine could potentially run into millions of dollars.
Apple submissions show it has submitted the "relevant turnover of Apple in India" for fiscal years 2022-24 as required — typically used by the watchdog for penalty calculations.
In the submissions, Apple is also arguing officials failed to grant the tech firm "a single opportunity to record its statements and provide oral evidence" during the probe.
Google was provided several opportunities to defend itself and explain its business model during its Android case, according to the Apple submission.
"While desirable, the CCI's investigation team is under no legal obligation to give an oral hearing if it feels it has conclusive evidence," said Gautam Shahi, an Indian antitrust lawyer at Dua Associates.
"CCI's members will now decide if Apple should have been given that opportunity."
As Apple diversifies iPhone manufacturing beyond China, India is a key market — the country is set to make 26% of the world's iPhones in 2026, up from 6% four years ago, according to Counterpoint Research.
If CCI does consider penalties, Apple said mitigating factors should be considered, including its "unblemished record" and the fact that it has exported iPhones worth $51 billion from India over the past five years.
Reporting by Aditya Kalra; Editing by Kate Mayberry
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Aditya Kalra is the Company News Editor for Reuters in India, overseeing business coverage and reporting stories on some of the world's biggest companies. He joined Reuters in 2008 and has in recent years written stories on challenges and strategies of a wide array of companies -- from Amazon, Google and Walmart to Xiaomi, Starbucks and Reliance. He also extensively works on deeply-reported and investigative business stories.
Apple lobbuje ve Washingtonu, aby mohla nakupovat paměťové čipy od CXMT, protože rostoucí ceny DRAM tlačí na její náklady. Firma už kvůli dražší paměti zdražila některé modely MacBook a iPad, což smazalo zhruba 263 miliard USD z její tržní hodnoty v jediném obchodním dni.
Apple is lobbying the Trump administration for clearance to buy memory chips from Chinese manufacturer CXMT as the artificial intelligence boom pushes up semiconductor costs and strains global supply chains, Financial Times reported on Saturday.
The move underscores how even the world's largest consumer electronics company is scrambling to secure additional sources of memory as demand from AI data centres reshapes the semiconductor market.
The report, citing six people familiar with the matter, said Apple has mounted a lobbying campaign across the White House and other parts of the administration to ease financial pressure from soaring memory chip prices, which recently forced the company to raise prices on several MacBook and iPad models.
According to the report, Apple first approached the Commerce Department more than a month ago and has since expanded its outreach to other administration officials and allies in Washington.
The company is seeking approval to source chips from ChangXin Memory Technologies (CXMT), one of China's leading DRAM manufacturers.
Apple is not currently prohibited from purchasing chips from CXMT or another Chinese memory producer, YMTC.
However, both companies have been placed on the Pentagon's Chinese Military Company blacklist over alleged links to the People's Liberation Army.
The Commerce Department also proposed adding CXMT to its Entity List last year, but the White House reportedly delayed the move while negotiating a trade truce with China.
People familiar with the discussions told the Financial Times that it remains unclear whether Apple will receive any assurances from the administration, particularly that CXMT will not later be added to the Entity List.
The uncertainty reflects broader tensions between Washington's national security priorities and the technology industry's growing dependence on semiconductor supply from Asia.
Last year, President Donald Trump approved Nvidia's sales of advanced H200 chips to China despite opposition from several administration officials.
Apple's lobbying efforts come after the company suffered one of its sharpest market setbacks in years following its decision to raise MacBook and iPad prices because of what it described as "unsustainable" memory costs.
The price increases erased about $263 billion from Apple's market value in a single trading session, its second-largest one-day decline.
Securing CXMT as an additional supplier would help reduce Apple's dependence on existing memory manufacturers at a time when AI infrastructure investment is absorbing a growing share of global DRAM production.
"The memory supply-demand gap will keep widening through 2027. That is the real reason Apple is lobbying the White House to keep CXMT off the Entity List," TF International Securities analyst Ming-Chi Kuo said in a post on X.
The memory supply-demand gap will keep widening through 2027. That is the real reason Apple is lobbying the White House to keep CXMT off the Entity List.
▌Start with my latest industry checks: The pressure on Apple has shifted from soaring memory costs to a widening supply gap.…
— 郭明錤｜Ming-Chi Kuo (@mingchikuo) June 28, 2026 He added that even successful lobbying would not fully resolve the shortage.
"CXMT states in its IPO prospectus that its capacity is far below domestic demand. Given the persistent global memory imbalance, even if Apple's lobbying succeeds and it buys DRAM from CXMT, that would not materially lower costs or fill the supply gap. Still, with the imbalance widening, Apple has every reason to secure an additional source."
Kuo said Apple's approach also differs from its earlier evaluation of YMTC in 2022.
"YMTC was mainly about lowering NAND costs; CXMT is about managing DRAM supply risk," he said.
He also suggested the lobbying effort carries reputational value regardless of the outcome.
"Tim Cook is one of the few tech leaders who can still navigate both Washington and Beijing, so this is better handled before he steps down as CEO. Even if the effort goes nowhere, the media coverage can still leave the market with the impression that Apple tried but was constrained by US policy. That may help ease frustration over price hikes and longer delivery times."
On the other hand, the tech giant's reported interest represents an important endorsement of CXMT's technological progress, regardless of whether Washington ultimately approves purchases, say analysts.
Citi analysts said obtaining permission could prove difficult given the current US political climate.
However, they argued that Apple's consideration of the company as a supplier already marks a shift in how investors view the Chinese memory maker.
"Regardless of whether Apple gets the purchase approval, its consideration of CXMT as a potential supplier shifts market perception of CXMT from a domestic substitution play to a credible global No.4 DRAM maker," Citi said in a research note.
Tesla, Sunrun a Renew Home oznámily rámec pro dodávku více než 16 GW flexibilní energetické kapacity pro hyperscalery a utility. Projekt využije miliony domácích baterií, chytrých termostatů a elektromobilů bez nového hardwaru.
Tesla stock is holding steady today. Where is TSLA stock headed? The NHTSA RollercoasterQ2 Deliveries on the HorizonOn June 24, Tesla, Sunrun, and Renew Home announced a framework to deliver more than 16 gigawatts of flexible energy capacity to hyperscalers and utilities, aggregating millions of existing home batteries, smart thermostats, and electric vehicles into what would be the largest distributed power plant in the country.
The framework requires no new hardware, software, or interconnection, and is deployable in months, not years. In Virginia alone, the companies have more than 300 megawatts available for immediate deployment, expected to grow to at least 500 megawatts by 2030. The deal puts Tesla’s Powerwall and energy ecosystem at the center of the AI data center power crunch narrative.
Tesla Shares GainTSLA Price Action: At the time of publication, Tesla shares are trading 0.89% higher at $383.09, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Microsoft čelí tlaku kvůli vysokým výdajům na AI infrastrukturu, ale jeden stratég tvrdí, že trh akcii výrazně přeceňuje na pokles. Tržby vzrostly o 18 % a EPS o 23 %.
Voting Against Short-Term FearsMicrosoft’s stock has faced relentless pressure as investors panic over massive capital expenditures. However, Boloor recently initiated a trade in the “former market darling,” arguing that Wall Street is “significantly overselling” Microsoft.
He attributes the recent sell-off to short-term fears regarding expensive AI infrastructure, GPU spending, and declining free cash flow.
Calling it a classic example of the voting machine versus the weighing machine, Boloor notes investors are punishing the stock today while ignoring the durable earnings power expected by 2027 and 2028.
Unignorable FundamentalsDespite the stock’s dismal year-to-date performance, the company’s core engine is accelerating. Overall revenue grew 18% year-over-year, and earnings per share expanded by 23%—meaning EPS is successfully outpacing revenue growth despite the heavy investments.
Most notably, Microsoft’s cloud segment surpassed $54 billion, with Azure soaring by 40%. Boloor points out that Microsoft possesses “one of the strongest enterprise distribution moats in all of technology.”
Rather than convincing companies to adopt brand new platforms, Microsoft is seamlessly embedding AI into everyday tools like Outlook, Excel, and Teams. This strategy brilliantly shifts the company from merely monetizing users to successfully “monetizing work.”
The Copilot Scale And OpenAI NuanceWhile some consider Copilot adoption disappointing, Boloor notes the platform already boasts over 20 million paid seats. As this scales, it transforms into a highly lucrative revenue layer.
Finally, Boloor addressed the OpenAI concentration risk. While acknowledging the vulnerability, he views the updated partnership as a “huge win” that allows Microsoft to retain vital IP rights through 2032 while redirecting capital toward its own internal AI infrastructure and Azure models.
How Has MSFT Performed In 2026?MSFT shares have plunged 22.88% YTD, up 10.35% over the last month, and 25.02% over the year. The stock closed 5.71% higher at $372.97 apiece on Friday, and it was 1.77% higher in premarket on Monday.
Benzinga’s Edge Stock Rankings indicate that MSFT maintains a weak price trend in the short, long, and medium terms, with a solid quality score.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
Market News and Data brought to you by Benzinga APIs
PepsiCo, Inc. (NASDAQ:PEP) will release its second quarter earnings report before the opening bell on Thursday, July 9.
Analysts expect the Purchase, New York-based company to report quarterly earnings of $2.21 per share, up from $2.12 per share in the year-ago period. The consensus estimate for Levi Strauss’ quarterly revenue is $23.97 billion. It reported $22.73 billion last year, according to Benzinga Pro.
On May 5, PepsiCo announced a new collaboration with TalusAg to advance fertilizer decarbonization via low-carbon ammonia environmental attributes.
PepsiCo shares gained 1.3% to close at $141.39 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying PEP stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Counterpoint uvedl, že Qualcomm má díky akvizicím a širšímu AI portfoliu potenciál nabídnout end-to-end AI infrastrukturu od hyperscale datových center po edge zařízení. Firma cílí na zhruba 15 miliard USD tržeb z AI datových center do fiskálního roku 2029.
The upbeat market backdrop comes as Counterpoint Research said Qualcomm is becoming one of the few semiconductor companies capable of delivering end-to-end AI infrastructure, spanning hyperscale data centers and edge devices.
AI Expansion Beyond Smartphones Gains CredibilityIn a research note published Friday following Qualcomm’s Investor Day, Counterpoint analyst Neil Shah said the chipmaker’s expanding AI portfolio and recent acquisitions position it as a credible full-stack AI solutions provider, with a path toward generating $100 billion in annual recurring revenue within the next five to seven years.
The analyst said Qualcomm’s diversification strategy extends well beyond smartphones and addresses the rapidly growing AI data center market, which remains in its early stages. The AI data center market is still in its infancy, and it is not a “zero-sum” game, Shah noted.
Acquisitions Build A Full AI StackCounterpoint highlighted Qualcomm’s recent acquisitions as key building blocks in its AI strategy.
The firm said NUVIA provides Qualcomm’s Oryon CPU architecture, enabling Arm-based processors that now span smartphones, PCs, automotive applications and future AI data centers.
Qualcomm also unveiled its C1000 server CPU, with Meta Platforms Inc. (NASDAQ:META) expected to become its first hyperscale deployment customer beginning around fiscal 2029.
The report also pointed to Qualcomm’s AI accelerator roadmap, custom silicon capabilities and its proprietary High Bandwidth Compute architecture, which aims to improve AI performance while reducing memory-related bottlenecks.
Counterpoint said the company’s recent acquisition of Modular strengthens its software stack by enabling AI workloads to run across different hardware platforms using an open architecture.
Data Center Opportunity Comes Into FocusCounterpoint said Qualcomm still faces gaps in networking and switching technologies, but noted that its acquisition of Alphawave Semi significantly expands its interconnect portfolio while bringing experienced leadership to its growing data center business.
The research firm also highlighted Qualcomm’s long-term financial targets unveiled during Investor Day. According to the report, management expects its AI data center business to generate about $15 billion in revenue by fiscal 2029, while the company’s non-handset businesses are projected to surpass handset revenue over the same period.
Automotive remains another major growth driver, with Qualcomm’s automotive design-win pipeline reaching $65 billion and expected to generate $10 billion in annual recurring revenue through fiscal 2029.
Counterpoint concluded that Qualcomm’s combination of silicon, software and ecosystem scale makes the company uniquely positioned to compete across the AI value chain, from hyperscale data centers to connected devices.
Technical Setup Remains MixedQualcomm continues to trade above its longer-term trend lines. The stock sits about 15.6% above its 100-day simple moving average of $166.92 and 14.9% above its 200-day simple moving average of $167.92.
However, the shares remain 11.3% below the 20-day simple moving average of $217.51 and 2.9% below the 50-day simple moving average of $198.72. That suggests the recent move is a rebound attempt rather than a confirmed recovery.
The 50-day moving average crossed above the 200-day moving average in May, forming a bullish “golden cross” that continues to support the intermediate-term trend. Even so, traders will likely look for the stock to reclaim the 50-day moving average before turning more bullish.
Momentum indicators remain cautious. The MACD remains below its signal line, indicating buying momentum has weakened following the previous rally.
Key technical levels to watch include resistance around $206, near the 50-day moving average, and support near $190.50, which aligns with a recent trading floor.
Earnings And Analyst OutlookQualcomm is expected to report quarterly earnings on or around July 29.
Wall Street expects earnings per share of $2.09 on revenue of $9.67 billion, compared with EPS of $2.77 and revenue of $10.37 billion in the year-ago quarter.
The stock trades at about 20.4 times earnings and carries a consensus Hold rating, with an average analyst price forecast of $209 based on coverage from 50 analysts. Recent analyst actions include:
Benchmark maintained Buy and raised its price forecast to $300 on June 25. Barclays maintained Underweight and increased its price forecast to $245 on June 25. UBS maintained Neutral and lifted its price forecast to $235 on June 25. Price ActionQCOM Stock Price Activity: Qualcomm shares were up 2.37% at $193.88 during premarket trading on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Intel je podle článku jediný z trojice HP, Intel a Xerox s reálným růstem: tržby vzrostly o 7,2 % na 13,577 miliardy USD a segment Data Center and AI vyskočil o 22 %.
Although HP (NYSE: HPQ | HPQ Price Prediction), Intel (NASDAQ: INTC), and Xerox (NASDAQ: XRX) each defined an entire category of American hardware, Wall Street no longer prices them as peers. One ticker has vaulted, one has drifted, and one is fighting for survival at a sub-$500 million market cap. The more useful frame is the IBM template: when a legacy hardware franchise pivots, survivors carry a real product-cycle catalyst, sufficient balance sheet runway, and operating leverage. Lou Gerstner’s 1990s mainframe-to-services rebuild is the yardstick, and only one of these three currently clears it.
Start with the scoreboard. Intel has climbed 470.3% over the past year and 283.7% since June 2023, closing at $128.32 on June 26. HP slipped 7.4% over the past year and 22.7% across three years, ending the same session at $22.88. Xerox has lost 38.3% over the past 12 months and 76.7% across three, finishing at $3.31. The Gerstner question is which move rests on a rebuild and which is noise.
HP: Managed Decline With a Cash Sleeve HP’s most recent quarter looks clean on the surface. Q2 FY26 revenue of $14.408 billion rose 8.99% year over year and beat consensus by 2.4%, while non-GAAP EPS of $0.86 beat the $0.72 estimate by 20.26%. Personal Systems surged 13%, Commercial PS jumped 14%, and free cash flow swung to $800 million from negative $100 million a year earlier. Management narrowed the full-year non-GAAP EPS band to $2.90 to $3.10.
However, the core franchise still carries mature-market scars. Printing was flat, Consumer Printing dropped 10%, total PC units fell 7%, and stockholders’ equity remained negative at –$144 million. A restructuring program targets roughly $1 billion in run-rate savings by FY2028 with 4,000 to 6,000 job cuts, while $100 million in buybacks and a $0.30 quarterly dividend return cash to shareholders. The thesis is cost discipline and capital return. That profile matches managed decline rather than Gerstner-grade reinvention.
Intel: High-Stakes Reinvention Intel’s Q1 FY26 earnings report is the closest match to the survivor profile in this group. Revenue of $13.577 billion grew 7.2% and beat by 9.22%, while non-GAAP EPS of $0.29 crushed the $0.0127 consensus estimate. Data Center and AI revenue vaulted 22% to $5.052 billion, and Intel Foundry grew 16% to $5.421 billion, now roughly 40% of total revenue. Non-GAAP gross margin expanded to 41.0% from 39.2%, marking the sixth consecutive quarter above revenue expectations.
The catalyst stack is tangible. A multiyear Google partnership covers Xeon and custom ASIC IPUs, Intel Xeon 6 was selected as the host CPU for NVIDIA’s DGX Rubin NVL8, and a Terafab project lines up SpaceX, xAI, and Tesla. A $5.0 billion NVIDIA equity investment and a U.S. government equity stake backstop the runway, while cash of $17.247 billion, up 92.77% year over year, funds the foundry buildout. CEO Lip-Bu Tan put it bluntly: “The next wave of AI will bring intelligence closer to the end user, moving from foundational models to inference to agentic. This shift is significantly increasing the need for Intel’s CPUs and wafer and advanced packaging offerings.” The tradeoffs are meaningful: a $4.07 billion Mobileye-related charge drove a $3.73 billion GAAP net loss, foundry remains unprofitable, and capex stays heavy. The profile matches genuine reinvention rather than a capex-cycle trade.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Xerox: Racing the Clock Xerox is running the abandon-the-old-battlefield script. The Lexmark deal and the ITsavvy and Powerland tuck-ins push the company toward IT and managed services. The balance sheet is the catch. Total liabilities stand at $9.37 billion against just $305 million of shareholders’ equity. Q1 2026 revenue of $1.846 billion rose 26.7% on acquisitions, but pro forma revenue declined 3.7%, and equipment gross margin collapsed to 10.8% from 27.9%, and adjusted EPS of negative $0.43 missed by 56.36%. Free cash flow ran to negative $165 million, and non-financing interest expense surged to $84 million from $33 million on acquisition debt.
CEO Louie Pastor told investors, “We are closer to an inflection point than the external narrative suggests.” The market disagrees. The analyst consensus price target is $2.75, with bearish sentiment, while trailing EPS stands at –$8.34, book value at $2.286, and the forward multiple at 3x. That is a credit-distress profile. The strategy fits the Gerstner playbook on paper. The capacity to execute it fits the Kodak playbook on the filings.
The Ranked Verdict Measured against the IBM survivor template (product-cycle catalyst, balance sheet capacity, operating leverage), the order is unambiguous.
Intel. The only profile here with a genuine AI tailwind, $17.247 billion in cash, NVIDIA and Google ecosystem validation, and margin expansion alongside a structural mix shift into foundry. HP. A disciplined operator with an FCF inflection and steady capital return, but no reinvention engine to anchor the next decade. Xerox. A textbook pivot attempted from a Kodak-shaped balance sheet. Direction is correct, runway is short. Long term, Wall Street keeps rewarding platform reinvention over hardware nostalgia. The decade-long tape says the same: Intel up 291.8% over a decade, HP up 86.6%, and Xerox down 86.7%. Same battlefield, three very different futures.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Merck uzavřel dohodu s ADAP Crisis Task Force, která má rozšířit přístup k IDVYNSO pro oprávněné osoby žijící s HIV. Programy ADAP v roce 2024 podporovaly v USA více než 250 000 lidí žijících s HIV.
Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individuals
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the company’s new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir). In 2024, state ADAPs supported more than 250,000 people with HIV in the United States.
IDVYNSO was approved by the U.S. Food and Drug Administration (FDA) in April 2026 as a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.
“ADAP programs play a critical role in supporting access to treatment for people living with HIV who are uninsured or underserved,” said Tim Horn, Director, Medication Access, National Alliance of State and Territorial AIDS Directors (NASTAD). “We appreciate Merck’s continued engagement and its willingness to work collaboratively to help address the critical access challenges facing state ADAP programs.”
“Merck is pleased to have reached this agreement with the ADAP Crisis Task Force to expand access to IDVYNSO for eligible people with HIV,” said Conrod Kelly, U.S. HIV business unit head, Merck. “This agreement reflects our long-standing commitment to working with the ACTF, state ADAPs and the HIV community to strengthen access and help address persistent gaps in care.”
For individuals with questions about coverage and affordability, the Merck Access Program may be able to provide information about insurance benefits, estimated out-of-pocket costs and co-pay assistance options for eligible patients.
The Merck Access Program for IDVYNSO
Merck offers support to individuals who are prescribed IDVYNSO, including information about patient insurance coverage and out-of-pocket costs, co-pay assistance for eligible, commercially insured individuals, and how individuals may access IDVYNSO through The Merck Access Program. For additional information, healthcare providers and individuals can call 1-877-709-4455 or visit https://www.merckaccessprogram-idvynso.com/.
About IDVYNSO
IDVYNSO is a fixed-dose combination of two medicines, doravirine and islatravir. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase. Islatravir is a potent, next-generation nucleoside analog reverse transcriptase inhibitor (NRTI) that blocks HIV-1 replication by multiple mechanisms including:
inhibition of reverse transcriptase translocation, resulting in immediate chain termination, and induction of structural changes in the viral DNA (delayed chain termination). Selected Safety Information for IDVYNSO
Contraindications
IDVYNSO is contraindicated when co-administered with:
drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of IDVYNSO. lamivudine (3TC) or emtricitabine (FTC) as significant decreases in islatravir-triphosphate (ISL-TP) concentrations may occur, which may decrease the effectiveness of IDVYNSO. (See Drug Interactions) Warnings and Precautions
Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during postmarketing experience with doravirine-containing regimens. In addition, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome) was reported with IDVYNSO in a clinical trial. Discontinue IDVYNSO, and other medications associated with these reactions, immediately if a painful rash with mucosal involvement, a progressive severe rash, or a rash with constitutional symptoms, eosinophilia, lymphadenopathy, or other organ involvement develops. Close clinical monitoring, and appropriate therapy should be initiated.
The concomitant use of IDVYNSO and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of IDVYNSO and possible development of resistance or possible clinically significant adverse reactions from greater exposures of a component of IDVYNSO.
Consider the potential for drug interactions prior to and during IDVYNSO therapy, review concomitant medications during IDVYNSO therapy, and monitor for adverse reactions. (See Drug Interactions)
Adverse Reactions
The most common adverse reactions (incidence ≥ 2%, all grades in any treatment group) reported in virologically suppressed participants in the IDVYNSO treatment groups in Trials 051 and 052, respectively, were: diarrhea (3% and 1%), dizziness (2% and 1%), fatigue (2% and 1%), abdominal distension (2% and 1%), headache (2% and 1%) and weight increased (2% and <1%).
A single case of severe immune thrombocytopenia (platelet count nadir of 2 x109/L) characterized by abrupt onset of subcutaneous hematoma, petechiae, and hematuria was reported in a participant 32 days after initiating IDVYNSO. The case resolved with discontinuation of IDVYNSO, in conjunction with treatments including corticosteroids and intravenous immunoglobulin (IVIG). Among all participants in Trials 052 and 051, there were no patterns of platelet decreases over time with IDVYNSO and no differences between treatment arms in mean change from baseline in platelet count.
Drug Interactions
IDVYNSO is a complete regimen; co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.
Co-administration of IDVYNSO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce the efficacy of IDVYNSO. If IDVYNSO is co-administered with rifabutin, one tablet of doravirine should be taken approximately 12 hours after the dose of IDVYNSO. Co-administration of IDVYNSO with other moderate CYP3A inducers is not recommended.
Co-administration of IDVYNSO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine.
Co-administration of IDVYNSO is not recommended with deoxycytidine kinase (dCK) substrates (e.g., nucleoside antimetabolites) as they may reduce the exposure of islatravir-triphosphate or with adenosine deaminase (ADA) inhibitors (e.g., pentostatin) as they may increase the exposure of islatravir. (see Contraindications)
Use in Specific Populations
There are insufficient human data on the use of IDVYNSO during pregnancy to inform a drug-associated risk of birth defects and miscarriage. Healthcare providers are encouraged to call the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263 to report pregnancy outcomes in individuals exposed to IDVYNSO.
It is unknown whether IDVYNSO or any of its components are present in human milk, affects human milk production, or has effects on the breastfed infant. Inform patients that the potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV-1), and (3) serious adverse reactions in a breastfed infant similar to those seen in adults.
Clinical trials in virologically suppressed participants who received IDVYNSO included 81 (11%) participants aged 65 years and older, including 10 (1%) aged 75 years and older. Overall differences in response have not been identified between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
No dosage adjustment of IDVYNSO is required in patients with eGFR ≥30 mL/min/1.73 m2. IDVYNSO is not recommended in patients with eGFR <30 mL/min/1.73 m2 and has not been studied in participants undergoing dialysis.
No dosage adjustment of IDVYNSO is recommended in patients with mild or moderate hepatic impairment (Child- Pugh Class A or B). IDVYNSO has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and therefore is not recommended in these patients.
IDVYNSO does not have activity against hepatitis B virus (HBV). Patients with HBV coinfection who switch to IDVYNSO from an antiretroviral regimen with activity against HBV, and patients on IDVYNSO who are newly diagnosed with HBV coinfection, should be closely monitored and specific anti-HBV therapy should be considered, as clinically appropriate.
Merck’s Commitment to HIV
For 40 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage HIV and protect people from HIV. We are researching for real life and want to ensure people are not defined by HIV. Our work focuses on transformational innovations, collaborations with others in the global HIV community and access initiatives aimed at helping to end the HIV epidemic for everyone.
About Islatravir (MK-8591) and Merck’s HIV Research
Islatravir (MK-8591) is Merck’s potent, next-generation nucleoside analog reverse transcriptase inhibitor (NRTI) that blocks HIV-1 replication by multiple mechanisms including inhibition of reverse transcriptase translocation, resulting in immediate chain termination, and induction of structural changes in the viral DNA (delayed chain termination).
Islatravir is approved in combination with Merck’s NNRTI, doravirine, in the United States and Japan as IDVYNSO™, a once-daily, single-tablet regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.
Islatravir is also under evaluation in multiple ongoing early and late-stage clinical trials in combination with other antiretrovirals for potential once-weekly treatments for HIV-1, in Merck's proprietary two-drug regimens.
Islatravir in combination with Gilead’s lenacapavir is in Phase 3 development as a novel oral once-weekly treatment for HIV-1 [ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299)], and islatravir in combination with Merck’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) ulonivirine (MK-8507) is in Phase 2b development (MK-8591B-060, NCT06891066 and MK-8591B-062, NCT07266831) as an oral once-weekly treatment.
MK-8527 is Merck’s investigational, novel, once-monthly, oral candidate for pre-exposure prophylaxis (PrEP) for HIV-1. In collaboration with the Gates Foundation, the Phase 3 EXPrESSIVE-10 trial (MK-8527-010, NCT07071623) trial is evaluating the safety and efficacy of MK-8527 as PrEP to reduce the risk of sexually acquired HIV-1 infection among women and adolescent girls in sub-Saharan Africa. The Phase 3 EXPrESSIVE-11 trial (MK-8527-011, NCT07044297) in 16 countries is evaluating the safety and efficacy of MK-8527 as PrEP to reduce the risk of sexually acquired HIV-1 infection among people likely to be exposed to HIV-1. Both trials are now enrolling.
For an overview of Merck’s HIV treatment and prevention clinical development program, please click here.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Please see Prescribing Information for IDVYNSO™ (doravirine and islatravir) at https://www.merck.com/product/usa/pi_circulars/i/idvynso/idvynso_pi.pdf and Patient Information for IDVYNSO at https://www.merck.com/product/usa/pi_circulars/i/idvynso/idvynso_ppi.pdf.
Palantir rozšiřuje partnerství se Surf Air Mobility a přidává zdroje pro rychlejší komerční rozvoj řešení OperatorOS, OwnerOS a SurfOS pro podnikové zákazníky. Spolupráce navazuje na úspěšné uvedení BrokerOS.
Following the successful commercial launch of BrokerOS, Palantir and Surf Air Mobility are committing additional engineering and go-to-market resources to accelerate commercial expansion of OperatorOS, OwnerOS, and SurfOS Enterprise Solutions.
MIAMI & LOS ANGELES--(BUSINESS WIRE)--Palantir Technologies Inc. (NASDAQ: PLTR) (“Palantir”) today announced an expansion of its partnership with Surf Air Mobility Inc. (NYSE: SRFM) (“Surf Air Mobility”), a leading air mobility platform. Under the expanded agreement, Palantir and Surf Air Mobility are committing additional resources to accelerate the development and commercial release of SurfOS, including OperatorOS, OwnerOS, and SurfOS Enterprise Solutions products.
The expanded partnership builds on the successful commercial launch of BrokerOS and the recent announcement of a multi-million-dollar contract with Wheels Up, a leading provider of on-demand private aviation, to be the launch customer for Enterprise BrokerOS.
SurfOS is powered by Palantir’s AIP and Foundry and is designed to bring modern software to the private aviation and air mobility industries, a segment that has historically relied on manual processes and fragmented, outdated software systems. SurfOS provides aircraft operators, brokers, owners, and manufacturers with the tools needed to manage operations, drive efficiencies, and reduce costs.
Expanded partnership highlights:
Dedicated resources to accelerate commercial expansion of OperatorOS, OwnerOS, and SurfOS Enterprise Solutions from Palantir and Surf Air Mobility Focused go-to-market support leveraging Palantir’s expertise in highly fragmented industries Expedited development product and feature development timelines, including the deployment of AIP agents across the SurfOS products Support establishing SurfOS as the central operating system for the next generation of private aviation and air mobility Ted Mabrey, Global Head of Commercial at Palantir, said: “Private aviation and air mobility are large, growing markets that have historically relied on fragmented systems and manual processes. With Foundry and AIP powering SurfOS, we see a clear opportunity to build and define the central operating system for the future of aviation and air mobility, and our expanded commitment reflects our conviction in Surf Air Mobility and the opportunity ahead.”
Liam Fayed, Co-Founder of Surf Air Mobility, said: “The expansion of our partnership with Palantir will enable us to deploy and expand SurfOS more rapidly into the end markets. BrokerOS showed what our companies can bring to market together, and the additional technical and commercial support from Palantir will help us accelerate that success across the rest of our SurfOS products.”
Each of Surf Air Mobility’s software products is geared toward different segments of the private aviation and air mobility market, including chartered air transport, private aircraft sales and MRO aftermarket. Surf Air Mobility believes SurfOS is positioned to capture value across these interdependent markets by creating a connected ecosystem where supply and demand are optimized by leveraging Palantir’s Foundry and AIP.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.
About Surf Air Mobility
Surf Air Mobility is a Los Angeles-based air mobility platform. With its AI-enabled SurfOS software, Surf Air Mobility provides technology designed to support the modernization of air operations and the adoption of next-generation aircraft. The Company currently operates one of the largest commuter airlines in the United States by scheduled departures and provides private charter services. Together, these businesses provide the operational scale and real-world operating data to validate and deploy its software. These capabilities position Surf Air Mobility as a leader shaping a more efficient, connected, and accessible future for aviation.
Palantir Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir's expectations regarding the amount and the terms of the contract and the expected benefits of Palantir's software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir's control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir's platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir's platforms’ reliability; and customers' ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Palantir’s forward-looking statements speak only as to Palantir, and Palantir assumes no responsibility for the accuracy or completeness of any forward-looking statements made by any other party. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
Surf Air Mobility Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Surf Air Mobility’s profitability and future financial results and its ability to achieve its business objectives. Readers of this release should be aware of the speculative nature of forward-looking statements. These statements are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company and reflect the Company’s current views concerning future events. As such, they are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among many others: Surf Air Mobility’s ability to anticipate the future needs of the air mobility market; Surf Air Mobility’s future ability to pay contractual obligations and liquidity will depend on operating performance, cash flow and ability to secure adequate financing; the dependence on third-party partners and suppliers for the components and collaboration in Surf Air Mobility’s development of its advanced air mobility software platform, and any interruptions, disagreements or delays with those partners and suppliers; the inability to execute business objectives and growth strategies successfully or sustain Surf Air Mobility’s growth; the inability of Surf Air Mobility’s customers to pay for Surf Air Mobility’s services; the inability of Surf Air Mobility to obtain additional financing or access the capital markets to fund its ongoing operations on acceptable terms and conditions; the outcome of any legal proceedings that might be instituted against Surf Air Mobility, the risks associated with Surf Air Mobility’s obligations to comply with applicable laws, government regulations and rules and standards of the New York Stock Exchange; and general economic conditions. These and other risks are discussed in detail in the periodic reports that the Company files with the SEC, and investors are urged to review those periodic reports and the Company’s other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov, before making an investment decision. The Company assumes no obligation to update its forward-looking statements except as required by law.
Micron těží z AI boomu: v posledním čtvrtletí tržby meziročně vzrostly z 9,3 miliardy USD na 41,5 miliardy USD a provozní zisk z 2,2 miliardy USD na 33,3 miliardy USD. Klíčové je, zda si udrží vysoké marže i v dalších letech.
Micron (MU 6.59%) stock has delivered extraordinary returns over the past year and a half. After a rally of more than 1,200% since the start of 2025, many investors will naturally assume the easy money has already been made on this stock. That may prove true.
But investors should remember something important: A stock does not become a bad investment simply because it has gone up sharply in price. The more relevant question is not about how much Micron stock has risen. It's about whether Micron can keep growing its profits. If the answer is yes, the stock could still have room to run.
Image source: Getty Images.
The stock doesn't need to get more expensive Many investors assume a stock can only rise significantly if investors become even more excited about it. That isn't always the case.
Imagine a company earns $10 billion in annual profits and investors value the business at $200 billion. That would give it a price-to-earnings ratio of 20. If profits eventually rise to $20 billion and the market keeps putting that same valuation on the company, its market cap would rise to $400 billion.
That hypothetical stock would have doubled even though investors had not become any more optimistic about the business. Rather, the business would have become more valuable because its profits rose.
Therein lies the basic bull case for Micron. If the company can continue to grow its profits, the stock can keep rising even if the valuation remains unchanged.
Today's Change
(
-6.59
%) $
-80.00
Current Price
$
1133.56
The bull case for why profits could continue to grow Micron sits at the center of one of the largest technology spending booms in decades.
Companies around the world are investing heavily in artificial intelligence infrastructure. The data centers they are building and equipping need capacious quantities of advanced memory to effectively handle the workloads involved in training and running increasingly powerful AI models. That surging demand has left the entire memory industry short on supply, which has helped Micron and its peers grow revenue and profits.
In the latest quarter, Micron's revenue more than quadrupled year over year from $9.3 billion to $41.5 billion, while operating profit surged more than tenfold from $2.2 billion to $33.3 billion.
At the same time, Micron is selling more of its most advanced memory products -- such as high-bandwidth memory -- for AI applications. That will help the company generate even greater profits from each dollar of revenue.
If AI infrastructure spending remains strong and data center clients continue buying premium memory products, Micron could sustain its current levels of profitability or keep growing its earnings over the next several years.
That possibility helps explain why some investors believe the stock can continue climbing even with a massive rally in behind it.
The real question investors should focus on While higher profits are desirable, the key question is not whether Micron can grow profits next quarter, but whether it can keep its profit margins high over the long term -- say, for the next five to 10 years.
That distinction matters. Many companies experience a few great years. But far fewer companies maintain strong profits for a decade or longer.
If Micron can continue earning more money year after year, the stock could still deliver attractive returns, even after its recent rally. On the other hand, if today's high margins prove temporary, the outcome will look very different.
What could go wrong? This is where investors need to be careful.
The memory industry has a long history of boom-and-bust cycles. Periods of strong demand often lead to strong profits. Strong profits encourage memory makers to expand their production capacity. But with multiple competitors following the same playbook at the same time, this has repeatedly led to the industry building capacity in excess of demand. When supply eventually catches up, their pricing power dissipates, and profits slide.
Micron has experienced this pattern over and over again across the decades. So the risk is not that the demand from the AI build-out will suddenly disappear. The risk is that the current situation represents an unusually good phase for sellers in a still-cyclical market rather than a new normal.
If Micron and its competitors increase production (which they are doing) and memory supply catches up with demand, Micron could face pressure on both pricing and profits.
What does it mean for investors? Can Micron stock double again? I think there's a good chance it can.
But investors should focus less on the stock price and more on the company's ability to keep growing profits. If Micron continues to benefit from AI spending and successfully expands its higher-margin memory business, earnings could continue to move higher. And if earnings keep growing, the stock could follow.
In other words, the most important question isn't whether Micron stock has already risen too much. It's whether the company can keep making more money, and for how long.
Those answers will likely determine where the stock will head next.
Jižní Korea spustila rozsáhlé investice do čipů za 800 bilionů wonů, tedy asi 518 miliard dolarů, což může časem zvýšit nabídku DRAM a HBM. Pro Micron to není okamžitá hrozba, ale tlak na cenovou sílu může později vzrůst.
Micron stock NASDAQ:MU is back in focus after South Korea unveiled a massive semiconductor expansion led by Samsung Electronics and SK Hynix.
For now, the plan is less a direct threat to Micron than a validation of the theme behind its rally: AI memory has become scarce, valuable and strategically important.
But the harder question is, if Samsung and SK Hynix spend hundreds of billions of dollars on new DRAM and high-bandwidth memory capacity, could today’s shortage eventually turn into tomorrow’s supply problem?
Micron’s latest results gave strong signals as the company delivered a blowout quarter, helped by AI demand, high-bandwidth memory shortages and strong pricing across the memory market.
More importantly, Micron showed that customers are no longer treating memory as a routine chip input.
They are trying to lock it in.
Micron has signed $22 billion in strategic customer commitments across data centre, consumer and automotive markets.
These agreements include take-or-pay terms, cash deposits and pricing floors.
In plain English, customers are committing ahead of time because they do not want memory supply to become the bottleneck that slows their AI buildouts.
Daniel Newman, CEO of Futurum Group, told Reuters that the scale of the AI buildout has been underestimated, and that memory should keep commanding “premium pricing” while supply remains constrained.
That is the core Micron bull case, as AI demand is running faster than supply, and MU is one of the few companies able to serve that market at scale.
But there is a catch. Analysts say Micron’s bull case still rests heavily on a tight memory market, and if fresh supply starts to return, pricing power could be the first part of the story to come under pressure.
South Korea’s new chip push is not aimed at Micron directly, but it changes the supply conversation.
Samsung Electronics and SK Hynix are preparing to invest 800 trillion won, or about $518 billion, in new chip fabrication sites as Seoul tries to cement the country’s lead in AI memory.
The wider plan is tied to President Lee Jae Myung’s industrial strategy, which aims to build semiconductor strength beyond existing hubs around Seoul.
For Samsung, the investment is partly a comeback strategy. The company remains one of the world’s biggest memory players, but SK Hynix and Micron have moved faster in high-bandwidth memory, the high-margin chip category used alongside AI processors.
The analysts at KB Securities-Jefferies noted that if Samsung qualifies successfully for next-generation HBM, the supplier structure could shift more toward SK Hynix and Samsung because of Samsung’s manufacturing capacity.
SK Hynix, meanwhile, is trying to defend the AI-memory crown it has built through Nvidia-linked HBM demand.
As per analysts, its customized AI memory has “fundamentally changed” industry economics and helped SK Hynix become the market leader.
For Micron investors, Korea’s $518 billion chip blitz is not an immediate sell signal.
As per experts, the new fabs will take years to build, and HBM qualification is difficult.
Customers do not switch suppliers overnight, and AI demand is still running ahead of available supply, which is why Micron has been able to secure long-term commitments and pricing protections in the first place.
The risk seems to be more about expectations.
Micron’s valuation has expanded because investors believe memory scarcity can last longer than in past cycles.
If Samsung and SK Hynix convince the market that a credible wave of new DRAM and HBM supply is coming after 2027, investors may start discounting weaker pricing power before the capacity actually arrives.
SK Hynix plánuje příští měsíc debut na Nasdaqu prostřednictvím ADR a může získat více než 29 miliard USD. Peníze chce použít na nové továrny a vybavení, což může zvýšit nabídku paměťových čipů a vyvinout tlak na ceny.
Massive demand for memory chips for artificial intelligence (AI) training and inference has been a boon for the three major memory chipmakers. Shares of Micron Technology (MU 6.59%) have climbed over 850% in the past year, while its Korean competitors SK Hynix and Samsung Electronics are up nearly 900% and 500%, respectively, in the same period. All three have benefited from a massive supply/demand imbalance, which has allowed them to charge record-high prices for their products.
Now SK Hynix is making a move that should be a warning to Micron investors and the memory market in general. The company will list American depositary receipts on the Nasdaq stock exchange next month. The offer could raise over $29 billion. Here's why Micron investors need to pay attention.
Image source: The Motley Fool.
A massive capital raise for Micron's biggest competitor While we're talking about trillion-dollar companies, make no mistake: $29 billion is still a huge amount of money to raise from the public market. Few other companies have ever raised that much at one time from a stock offering.
That capital has to come from somewhere. With Micron being the only one of the big three memory chipmakers with U.S.-listed shares, it may feel the brunt of the shift in capital as investors look to broaden exposure in the memory market.
The bigger thing Micron investors need to worry about, however, is exactly what SK Hynix plans to do with all that cash. In its SEC filing, management said it intends to use all proceeds to construct new production facilities in Korea and to purchase new fabrication equipment.
Those facilities could start producing new chips before the end of 2027, with a rapid ramp-up in capacity through 2030. It's also constructing an advanced chip packaging facility in Indiana that's set to open in 2028.
Today's Change
(
-6.59
%) $
-80.00
Current Price
$
1133.56
SK Hynix's expansion plans could rapidly increase the total supply of memory chips in a market where products are mostly commoditized. SK Hynix chips can be used in place of Micron chips. As a result, if SK Hynix has more chips to sell, it could gain market share and put pressure on pricing.
Of course, Micron isn't standing still. It's building two factories in Idaho, which are set to open in 2027 and 2028. It also acquired a site in Taiwan where it expects to start production in mid-2027, and it's planning additional projects set to start production later this decade. Overall, management expects supply constraints to persist through the end of next year.
As more supply comes online to meet demand, prices will fall. Overall profits can continue to climb for some time, as more unit sales offset declining market prices. However, profits will eventually fall as supply growth outpaces demand growth, with SK Hynix, Micron, and Samsung all racing to build capacity. SK Hynix's capital raise could accelerate that peak.
Micron investors should exercise caution The current upward earnings cycle in the memory chip market can't last forever. Micron is already taking steps to protect itself against what could be a severe downcycle in a few years. It's signing long-term strategic customer agreements that lock in pricing at a maximum equal to its current price, while also creating a pricing floor.
Many of those agreements run through 2030, and management says they represent about 20% of its dynamic random-access memory (DRAM) chip volume. The agreements could reduce the cyclical downturn later this decade, but it also caps the upside it could generate over the next year or two from increased pricing.
With SK Hynix's aggressive build-out plans about to receive significant capital backing, Micron may be betting on an accelerated timeline toward the market's peak pricing.
The stock price has climbed to about 9 times forward earnings expectations and 8 times fiscal 2028 earnings expectations. If Micron's earnings cycle peaks, as expected, in 2028, it's currently trading for a relatively expensive multiple compared to its historic valuation. If the competition pushes that timeline forward or worsens the downcycle, it could prove way overvalued at today's price.
Nový CEO Occidental Richard Jackson chce v blízké době snížit dluh na 10 miliard USD a zlepšit volný cash flow. Firmu zároveň dál zatěžují vysoké dividendy Berkshire.
SummaryCompaniesCEO Richard Jackson aims to cut debt to $10 billionOccidental to begin repaying $8.5 billion to Berkshire in 2029Investor Bill Smead says Occidental must grow or seek a buyerHOUSTON, June 29 (Reuters) - In not quite a month as Occidental Petroleum's (OXY.N), opens new tab CEO, Richard Jackson has already been challenged with looking for ways to lift a lagging stock price and pay down more debt.
Longer term, Jackson may face a more fundamental question: whether to seek a buyer for the oil company that has a roughly $51 billion market cap.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Berkshire Hathaway (BRKa.N), opens new tab, whose preferred stake costs Occidental hundreds of millions of dollars in annual dividends, already owns a quarter of the company.
Jackson, who first joined Occidental in 2003, took over the Houston-based company on June 1. He succeeded Vicki Hollub, who ran Occidental for a decade and engineered two major acquisitions that shifted Occidental's oil production heavily toward the U.S.
That positioning has proved advantageous as the U.S.-Israeli war with Iran rattled confidence in Middle East oil supply. Rivals like Exxon Mobil, with roughly 20% of its production in the region, were more exposed to disruptions.
Yet Occidental's acquisitions came at a steep cost and saddled the company with as much as $38.5 billion in long-term debt. Hollub reduced the debt to $15.2 billion by the end of her tenure, during which the share price fell 26%, lagging far behind its peers. Over the same time period, ConocoPhillips returned 153% and Chevron returned 88%.
"The biggest opportunity is to clean up the capital structure, strengthen the balance sheet and increase shareholder returns," said David Byrns, a portfolio manager at American Century Investments, which holds an Occidental stake worth about $131 million, according to LSEG data.
During an earnings call in May, Jackson said his priority was to reduce principal debt to $10 billion in the near term, continue boosting free cash flow and grow oil production organically through technology.
"Richard has been spending time meeting with investors, hearing their points of view and reinforcing that our value improvement starts with executing from a strong balance sheet," an Occidental spokesperson said. GETTING OUT FROM UNDER BERKSHIRE
Occidental acquired Anadarko Petroleum for $55 billion including debt in 2019, aided by a $10 billion investment from Berkshire that requires Occidental to pay the conglomerate an 8% annual dividend. That is a higher payout than the typical junk bond now offers, and spurred criticism that Occidental was rewarding Berkshire much more than its other shareholders.
Occidental has paid off about $1.5 billion of the preferred stock and plans to begin redeeming the rest at a 5% premium when it is eligible to do so in August 2029.
Berkshire also owns 26.9% of Occidental's common stock, with warrants to buy $5 billion more until one year after Occidental redeems the preferred stock.
As a leader, Jackson proved successful at turning around a previously dysfunctional global drilling team, and is well-liked within the company, a former Occidental executive said.
Despite operational improvements so far, Occidental must either make more acquisitions or look for a buyer, said Bill Smead, chief investment officer at Smead Capital Management, which owns a roughly $201 million Occidental position.
The oil industry has seen a wave of mega-mergers in recent years, as producers sought to consolidate and lower operational costs.
"Either Occidental needs to get bigger and beef up the oil in the tank, or they're probably going to have to be part of a larger oil and gas company," Smead said.
Occidental and Berkshire should make clear whether they intend for Occidental to eventually become a subsidiary of the conglomerate, he added. Billionaire Warren Buffett, who was Berkshire's CEO at the time of its investment in Occidental, has said he did not plan to buy the company. Berkshire, whose new CEO is Greg Abel, declined to comment.
Berkshire's large stake limits interest in Occidental from potential acquirers, Smead said. "It keeps other investors from being aggressive."
Reporting by Sheila Dang in Houston; Additional reporting by Jonathan Stempel; Editing by Nathan Crooks and David Gregorio
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Honeywell Technologies oznámila, že ve čtvrtek 23. července zveřejní hospodářské výsledky za 2. čtvrtletí před otevřením burzy Nasdaq a probere výhled na rok 2026. Součástí budou i výsledky bývalé Aerospace Technologies, nyní Honeywell Aerospace (HONA).
, /PRNewswire/ -- Honeywell Technologies (NASDAQ: HON) today announced it will issue its second quarter financial results before the opening of the Nasdaq Stock Market on Thursday, July 23. The results for the second quarter will include the former Aerospace Technologies segment, which is now operating as Honeywell Aerospace and trading on Nasdaq under the ticker symbol "HONA" following the spin-off from Honeywell today. Honeywell Technologies will hold a conference call at 8:30 a.m. EDT to discuss its second quarter performance and 2026 outlook.
Presentation Materials / Webcast Details
A real-time audio webcast of the presentation can be accessed at investor.honeywell.com, where related materials will be posted prior to the presentation and a replay of the webcast will be available for 30 days following the presentation.
Honeywell Technologies is a global, pure-play automation company with a legacy of innovating to help solve the world's most mission-critical challenges, enhancing the quality of life for people and communities around the world. We serve the building, industrial, and process sectors with a broad portfolio of services, solutions, and products, underpinned by our Honeywell Technologies Accelerator operating system and Honeywell Technologies Forge intelligence layer. By combining the deep domain expertise of our more than 50,000 employees with decades of data from our global installed base, we are uniquely positioned to lead the industrial sector's transition from automation to autonomy. For more news and information on Honeywell Technologies, please visit Honeywell Technologies Newsroom.
Honeywell Technologies uses our Investor Relations website, investor.honeywell.com, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.
June 29, 2026 06:55 ET | Source: Scotts Miracle-Gro Company (The)
Nate Baxter Appointed President and Chief Executive Officer
Pete Shumlin Elected Chairman of the Board
MARYSVILLE, Ohio, June 29, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, today announced that the Board of Directors has named Nate Baxter as president and CEO, effective immediately. In addition, Baxter has joined the Board of Directors. The Board also elected independent Lead Director Pete Shumlin as chairman of the Board.
Baxter succeeds Jim Hagedorn, 70, CEO since 2001 and chairman since 2003, whose transition from the Company and its Board of Directors aligns with the Board’s long-term internal succession plan. The framework of the succession plan was established by the Board of Directors upon Baxter joining the Company in 2023.
During his tenure, Baxter, 53, has driven a relentless focus on operational excellence and is the architect of the Company’s multi-year SMG 2.0 growth strategy centered on category growth, channel expansion and product innovation grounded in naturals and organics. He also has spearheaded the implementation of technology, automation, data analytics and AI to deliver operational and cost efficiencies throughout the organization.
Hagedorn completed a nearly 40-year career with the Company, having held sales, operations and management roles before becoming CEO and chairman. Hagedorn, whose father Horace started Miracle-Gro in 1951, led the merger of the family business with The Scotts Company in 1995. In his time as CEO, he shaped the modern lawn and garden industry through acquisitions of key brands, such as Ortho and Tomcat, that significantly expanded the portfolio and through strategic growth initiatives that included the joint venture with Bonnie Plants. He advanced new approaches to consumer marketing and led the public listing of SMG on the New York Stock Exchange. Annual revenue climbed from $732 million in 1995 after the Scotts and Miracle-Gro merger to $3.3 billion in fiscal 2025.
“Jim has made ScottsMiracle-Gro what it is today and fundamentally modernized the lawn and garden industry by championing the consumer experience,” Shumlin said. “As a former F-16 fighter pilot, he brought a boldness and competitive spirit to the Company that remains a big part of the associate experience. He has given most of his adult life to this Company, and we are eternally grateful.
“As for Nate’s appointment as chief executive officer, this is the realization of the Board’s internal succession planning efforts with an eye toward accelerating next-generation growth drivers to scale the business. Nate has proven to be an exceptional talent who leads with integrity, collaboration, vision and operational expertise. He is the architect of the SMG 2.0 growth plan and has built a strong team to execute upon it. He is uniquely qualified to further evolve ScottsMiracle-Gro into the essential, lifestyle brand for lawn and garden consumers of today and the future.”
Baxter added, “I consider it a tremendous privilege to lead ScottsMiracle-Gro and serve all those we touch daily. I know I have big shoes to fill and look forward to collaborating with our teams as we nurture a culture in which our associates thrive and work together to deliver on the SMG 2.0 strategy. We have a special consumer franchise with a meaningful runway. My focus is to build on the momentum of SMG 2.0 while maintaining the financial discipline that has strengthened our balance sheet, converting that into durable shareholder value creation.”
Hagedorn said, “It has been an honor to be part of this Company for most of my life. I’m grateful for the opportunity to work with so many talented people as we built ScottsMiracle-Gro and its brands into the market leader with superpowers like no other in lawn and garden. Nate is ready to take over the reins. He has established himself as the leader ScottsMiracle-Gro needs as it transforms for the future.”
Fiscal 2026 Outlook
In connection with today’s announcement, the Company has reaffirmed its previously provided Fiscal 2026 guidance, which includes:
U.S. Consumer net sales low single-digit growthNon-GAAP adjusted gross margin of at least 32%Non-GAAP adjusted net income per share from continuing operations of $4.15 to $4.35Non-GAAP adjusted EBITDA mid single-digit growthFree cash flow of approximately $275 million, driving leverage ratio down to the high 3s
As previously announced, the Company will host its 2026 Investor Day at the New York Stock Exchange on August 4, 2026, beginning at 9 a.m. ET. Members of the executive and senior leadership team will discuss the Company’s mid- to long-term strategic priorities and financial goals followed by a question-and-answer session.
Bios
Baxter joined the Company in April 2023 as executive vice president, technology and operations, and was named COO in September 2023 before taking on the expanded role of president and COO in 2024. Among his responsibilities were execution of Company strategies and oversight of the market-leading brands, sales, supply chain, marketing, R&D and information technology. Prior to ScottsMiracle-Gro, Baxter was president of TEL U.S., a Tokyo Electron Ltd. subsidiary that manufactures semiconductor and flat-panel manufacturing equipment, and worked with Intel Corporation in technology, supply chain, strategy and management. He is a general partner of the Hagedorn Partnership, L.P., the largest shareholder of the Company, and serves as chairman of the board of Bonnie Plants, the largest national supplier of vegetable and herb plants in the U.S., as well as a board member with The Legacy Project, which empowers students to become leaders and innovators.
Shumlin, 70, a former three-term governor of Vermont and director at Putney Student Travel as well as a principal in numerous real estate ventures, has been a member of the Board of Directors since 2017 and served as its lead independent director since 2023.
About ScottsMiracle-Gro
With approximately $3.3 billion in sales, the Company is the leading marketer of branded consumer lawn and garden products in North America. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro®, Ortho® and Tomcat® brands are market-leading in their categories. For additional information, visit us at www.scottsmiraclegro.com.
For investor inquiries:
Brad Chelton
Vice President
Treasury, Tax and Investor Relations [email protected]
(937) 309-2503
For media inquiries:
Tom Matthews
Chief Communications Officer [email protected]
(937) 844-3864
Viatris oznámil pozitivní výsledky fáze 3 pro VR-205 u japonských dospělých s primární IgAN; lék splnil hlavní i klíčové sekundární cíle a byl dobře snášen. Podání žádosti o registraci v Japonsku směřuje do konce roku 2026.
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated
VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies
Japanese New Drug Application Submission Targeted by End of 2026
, /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease.
The Phase 3 clinical trial was a multicenter, interventional, open-label study designed to evaluate the efficacy and safety of 16 mg of VR-205 in Japanese adult patients with primary IgAN. Patients were treated for nine months, followed by a three-month follow-up period.
The study achieved its primary endpoint, with VR-205 demonstrating a 33.75 percent reduction in geometric mean urine protein-to-creatinine ratio (UPCR) at 9 months compared to baseline [95% CI: -45.27 to -19.80; p < 0.001]. These results were statistically significant and clinically meaningful, and were consistent with those observed in the global Phase 3 program for the product. Key findings included:
In addition to a statistically significant and clinically meaningful reduction in UPCR at 6 and 12 months, VR-205 demonstrated a significant improvement in estimated glomerular filtration rate (eGFR) and reductions in serum creatinine and urine albumin-to-creatinine ratio (UACR) at 9 months compared to baseline. The overall therapeutic benefit of VR-205 was further supported by improvements in microhematuria and a sustained proteinuria reduction. No study participants progressed to dialysis, kidney transplant or severe renal impairment (eGFR ≤15 mL/min per 1.73 m2) by the end of the study. VR-205 was generally well tolerated over the nine-month treatment period, with a safety profile consistent with the known safety profile of targeted-release budesonide in non-Japanese patients. "We are pleased with these top-line results, which highlight VR-205 as a potentially meaningful, disease-modifying treatment option for patients with primary IgAN," said Viatris Chief R&D Officer Philippe Martin. "In Japan, where IgAN incidence is the highest globally, VR-205 could become the first IgAN-specific, targeted-release budesonide oral therapy. This progress reflects the continued execution of Viatris' strategy focused on building a differentiated and increasingly innovative portfolio in Japan, with an emphasis on delivering therapies that provide meaningful value and address significant unmet needs."
"Primary IgAN is a designated intractable disease in Japan, and remains a significant unmet need, with no curative treatment despite the risk of progression to end-stage renal disease," said Yuko Asami, Head of R&D, Viatris Japan. "These top-line results mark an important step toward expanding treatment options for patients and healthcare providers."
Viatris is targeting submission of a New Drug Application in Japan by the end of 2026.
In 2022, Calliditas Therapeutics AB and Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc., entered into an exclusive license agreement to obtain marketing authorization and to commercialize VR-205 for the treatment of primary IgAN in Japan. It is currently a specialty drug approved and marketed as Tarpeyo® in the U.S. and as Kinpeygo® in Europe.
About Phase 3 Study (VR-205A-01-CAZ-3001)
The Phase 3 trial was a multicenter, interventional, open-label study conducted in Japan to evaluate the efficacy and safety of oral VR-205 (targeted-release budesonide formulation) for the treatment of primary IgA nephropathy in Japanese adult patients at risk of developing end-stage renal disease. The study enrolled a total of 39 participants who were treated with 16 mg of VR-205 daily (four capsules) over a nine-month treatment period.
Following completion of treatment, participants entered a three-month follow-up period including a two-week dose tapered to 8 mg of VR-205 (two capsules) daily at the start of the follow-up period.
About Immunoglobulin A Nephropathy (IgAN)
IgAN is a progressive, immune-mediated kidney disease and the most common primary glomerulonephritis worldwide. Japan reports the highest incidence rates globally, at 39 to 45 cases per million population per year, with peak age at diagnosis between 30 and 39 years. In Japan, adult-onset IgAN is reported to progress to end-stage renal disease (dialysis or transplantation) in approximately 15-20 percent of patients within 10 years. Most patients reaching end-stage renal disease face decades of dialysis. The total national cost of maintenance hemodialysis in Japan is approximately JPY 1.5 trillion per year. Chronic glomerulonephritis (with IgAN as a leading underlying cause) accounts for 23.4 percent of Japan's more than 340,000 dialysis patients. Despite this burden, therapies that target the underlying immunological drivers of IgAN to preserve long-term kidney function have remained limited, and a clear need persists for disease-modifying treatment options.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease; VR-205 met primary endpoint and key secondary endpoints, and was well tolerated; VR-205 efficacy and safety profile in Japanese patients was statistically significant and clinically meaningful and were consistent with the profile observed in global studies; we are pleased with these top-line results, which highlight VR-205 as a potentially meaningful, disease-modifying treatment option for patients with primary IgAN; in Japan, where IgAN incidence is the highest globally, VR-205 could become the first IgAN-specific, targeted-release budesonide oral therapy; this progress reflects the continued execution of Viatris' strategy focused on building a differentiated and increasingly innovative portfolio in Japan, with an emphasis on delivering therapies that provide meaningful value and address significant unmet needs; these top-line results mark an important step toward expanding treatment options for patients and healthcare providers; Viatris is targeting submission of a New Drug Application in Japan by the end of 2026. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.
Biogen na AAIC 2026 ukáže nová data z fáze 2 studie CELIA pro diranersen u časné Alzheimerovy choroby, včetně klinických, biomarkerových a bezpečnostních výsledků. Představí také nové analýzy lecanemabu.
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experienceAdvances across Biogen’s Alzheimer’s disease portfolio underscore its leadership and continued commitment to innovation in Alzheimer’s care, spanning treatment delivery, real-world evidence and approaches targeting core pathologies, including amyloid and tau
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).
“Biogen remains committed to advancing innovation across Alzheimer’s care, from treatment delivery and real-world evidence generation to continued progress in addressing core pathologies, including amyloid and tau. Tau has long remained one of the most important targets in Alzheimer’s disease, and the Phase 2 CELIA topline results for diranersen reinforce the potential of tau reduction as a therapeutic approach in early Alzheimer’s disease,” said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. “We look forward to presenting initial data from this pioneering study as well as new data on lecanemab on the global stage at AAIC.”
Featured Scientific Sessions and Presentations
Diranersen
Diranersen is an investigational ASO that targets MAPT RNA to reduce tau production at its source, a differentiated approach to addressing abnormal tau both inside and outside neurons. At AAIC, Biogen will present clinical, biomarker and safety data that build on the May 2026 topline announcement and further characterize diranersen as the program advances toward Phase 3 development.
Topline Results from CELIA: A Phase 2 Study to Evaluate the Tau-Targeting ASO Diranersen (BIIB080) in Patients with Early Alzheimer’s Disease
Developing Topics Session: Developing Topics in Phase 2 Clinical Trials,
Tuesday, July 14, 2:00–3:30 PM BST This presentation will feature data from CELIA, an 18-month Phase 2 study evaluating diranersen, Biogen’s investigational tau-targeting ASO, in patients with early Alzheimer’s disease. The presentation will include initial clinical, biomarker and safety results from the study.
Lecanemab
Featured lecanemab sessions at AAIC will highlight continued progress in the treatment landscape for early Alzheimer’s disease, with data spanning subcutaneous administration, including at-home use, practical treatment considerations, and three-year real-world evidence from the multicenter LEADER study.
Developing Topics Session: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations
Sunday, July 12, 4:15–5:45 PM BST This session will feature presentations on the emerging clinical evidence, safety profile, practical use considerations and real-world patient experience with subcutaneous lecanemab administration in early Alzheimer’s disease.
Featured Research Session: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse U.S. Clinical Settings
Tuesday, July 14, 4:15–5:45 PM BST This session will feature new real-world evidence from the LEADER study, including findings on lecanemab use and outcomes across diverse U.S. clinical settings, once-monthly maintenance dosing, patient pathways and physician and perceived patient satisfaction with maintenance therapy.
Selected Additional Oral and Poster Presentations
The following selected presentations highlight additional areas of Alzheimer’s disease research being presented at AAIC, including lecanemab-related data. For a complete list of presentations, please refer to the AAIC scientific program.
Real-world Insights into Clinician Involvement and Testing Approaches for Mild Cognitive Impairment and Alzheimer’s
Monday, July 13, 7:30 AM–4:15 PM BST Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Disease
Monday, July 13, 7:30 AM–4:15 PM BST
Lecanemab Treatment for Alzheimer’s Disease in Real-World Clinical Practice: A Multicenter, Surveillance Safety Study from the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry
Tuesday, July 14, 9:00–10:30 AM BST
Impact of Biomarker Modalities in the Diagnostic Evaluation of Patients with Suspected Alzheimer’s Disease: A US Retrospective Study
Wednesday, July 15, 7:30 AM–4:15 PM BST Estimating the Economic Impact of Delayed Alzheimer’s Disease Progression with Lecanemab
Wednesday, July 15, 7:30 AM–4:15 PM BST Educational Program on Tau in Alzheimer’s Disease
At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer’s disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on KnowTau.com, building on the resources already available.
For more information, please see the AAIC 2026 program and visit the Biogen AAIC booth.
About diranersen (BIIB080)
Diranersen (BIIB080) is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Unlike many investigational approaches that have focused on targeting extracellular tau, diranersen is designed to reduce both intracellular and extracellular tau.
Diranersen is being investigated as a potential treatment for early Alzheimer’s disease. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease.
In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was discovered by Ionis.
About the CELIA Study
CELIA is a global Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. All participants enrolled in CELIA had not previously received anti-amyloid therapy.
The study evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months, and 115 mg every three months.
The primary endpoint of CELIA was assessment of dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory endpoints included additional clinical, biomarker and imaging measures, including cerebrospinal fluid tau biomarkers and tau positron emission tomography (PET). Additional information on the CELIA study design is available in the ClinicalTrials.gov listing for the CELIA study.
An ongoing long-term extension (LTE) study is continuing to evaluate the long-term safety, tolerability and durability of diranersen in early Alzheimer’s disease.
About LEQEMBI ® (lecanemab)
LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble protofibril and insoluble forms of amyloid beta (Aβ). LEQEMBI is indicated in the U.S. for the treatment of Alzheimer’s disease and treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. Lecanemab has been approved in 53 countries and regions, including Japan, the United States, China, Europe, South Korea, Taiwan and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial treatment phase with intravenous dosing every two weeks for 18 months, intravenous maintenance dosing every four weeks has been approved in 7 countries, including the U.S., China and the UK, with applications filed in additional countries and regions. In the U.S., FDA approved LEQEMBI IQLIK™ for once-weekly subcutaneous maintenance dosing in August 2025. A supplemental Biologics License Application for LEQEMBI IQLIK as a once-weekly subcutaneous starting dose is currently under FDA Priority Review, with a Prescription Drug User Fee Act action date of August 24, 2026.
Eisai and Biogen have been collaborating on the joint development and commercialization of Alzheimer’s disease treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential benefits, efficacy and safety of diranersen (BIIB080) and lecanemab (LEQEMBI); the potential to advance care and improve outcomes for, and address unmet needs of, patients with Alzheimer’s disease; potential regulatory discussions, submissions, decisions and approvals and the timing thereof; the anticipated benefits, risks and potential of our collaboration arrangements; the potential of our commercial business and pipeline programs, including Biogen’s Alzheimer’s disease portfolio; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Digital Media Disclosure
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.
EXIM schválil financování FuelCell Energy ve výši 49 milionů USD na podporu vývozu americké čisté energetiky. První tranše má podpořit dodávku pěti bloků o výkonu 2,8 MW do Gyeonggi Green Energy v Jižní Koreji.
June 29, 2026 07:30 ET | Source: FuelCell Energy, Inc.
DANBURY, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) announced that the Board of Directors of the Export-Import Bank of the United States (EXIM) approved a financing package on June 23, 2026, of $49 million to be disbursed in two tranches.
The first tranche, expected to disburse on June 30, 2026, provides the company with net proceeds of approximately $22 million after financing fees and customary expenses and reserves to support the delivery of five 2.8-megawatt (MW) FuelCell Energy Blocks to Gyeonggi Green Energy (GGE) in South Korea. With nearly 60 MW of installed capacity, GGE’s site is among the largest fuel cell installations in the world and serves as an important example of distributed utility-scale clean energy deployment. A second tranche is expected to be disbursed in October 2026, subject to customary closing conditions.
EXIM structured the financing under its loan guarantee program and arranged with Private Export Funding Corporation (PEFCO), supporting the export of American clean energy technology to international markets. It builds upon FuelCell Energy’s prior EXIM-supported financing completed in 2024 and 2025 and reflects continued support for the company’s export of U.S.-manufactured clean energy technology.
“EXIM’s approval validates the strength of this project, our partnership with Gyeonggi Green Energy, FuelCell Energy’s business plan, and our ability to deliver distributed utility-scale clean power globally,” said Michael Bishop, FuelCell Energy’s Chief Financial Officer. “This financing adds non-dilutive capital to support growth and provides added flexibility as we invest in scaling manufacturing capacity, pursuing strategic opportunities in global power markets and mirroring our distributed utility scale solutions to AI factories and data centers.”
FuelCell Energy manufactures its clean, baseload fuel cell technology in Torrington, Conn., supporting domestic manufacturing, U.S. supply chains, and skilled American jobs. The transaction aligns with EXIM’s mission to support U.S. manufacturing, exports, and global competitiveness. Approximately 90% of the content in FuelCell Energy Blocks is sourced from the United States.
About FuelCell Energy
FuelCell Energy, Inc. is an American clean energy technology company delivering continuous, scalable baseload power for mission critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.fuelcellenergy.com.
Global Net Lease od začátku druhého čtvrtletí prodala aktiva za 74 milionů USD, z toho 66 milionů USD obsazených nemovitostí, včetně 61 milionů USD kancelářských aktiv s hotovostní cap rate 7,2 %. Tím dál snižuje expozici vůči kancelářím.
June 29, 2026 06:00 ET | Source: Global Net Lease, Inc.
Sold $66 Million of Occupied Properties, Including $61 Million of Office Assets at a 7.2% Cash Cap Rate Office Assets Accounted for 93% of Occupied Sales Disposition Activity Reduces Office Exposure and Supports Continued Focus on Leverage ReductionPending Acquisition of Modiv Industrial Remains on Track for Anticipated Third Quarter 2026 Closing NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (NYSE: GNL) ("GNL" or the "Company") today announced that, since the first quarter 20261, it sold $74 million of assets, including $66 million of occupied assets at a 7.2% cash cap rate, with office assets representing $61 million, or 93%, of occupied dispositions. GNL also sold $8 million of vacant assets, eliminating negative NOI drag, increasing portfolio occupancy and enhancing overall portfolio quality. Year-to-date, GNL has now closed approximately $145 million of dispositions at a 7.5% cash cap rate on occupied assets.
Since the first quarter 20261, GNL sold two occupied office assets at a 7.2% cash cap rate: a 33,000-square-foot building leased to the U.S. General Services Administration ("GSA") for $13 million and a 369,000-square-foot office building leased to GE Aviation for $48 million. Prior to the sales, GNL executed 20-year and 10-year lease extensions at the GSA and GE Aviation properties, respectively, increasing the assets' marketability and positioning them for dispositions at enhanced values. In addition, GNL has a 133,000-square-foot office asset in the Netherlands, currently leased to Koninklijke KPN N.V. ("KPN"), under contract for sale for approximately $18 million2, upon the expiration of KPN's lease in December 2026. These transactions reflect the Company's continued execution of its strategy to reduce office exposure, proactively address lease rollover risk, and improve the long-term quality of the portfolio. GNL is continuing its efforts to further reduce its office exposure and looks forward to providing additional details for any potential transaction entered into. Upon completion of these transactions, GNL expects office exposure to be reduced to approximately 21% of portfolio straight-line rent.
On the acquisition front, GNL is currently under contract to acquire a 100,000-square-foot single-tenant industrial property occupied by a Fortune 50 investment-grade tenant for $14 million at an 8.2% cash cap rate. The Company anticipates that this acquisition will provide an opportunity to redeploy disposition proceeds into a high-quality industrial asset at an attractive yield.
Together with the pending $535 million acquisition of Modiv Industrial, Inc. (NYSE: MDV), expected to close in the third quarter of 2026, these initiatives reflect GNL's continued focus on increasing exposure to single-tenant industrial and retail assets while strategically reducing office concentration. The acquisition is expected to be immediately 4% accretive to AFFO per share and is structured to be leverage neutral, complementing GNL's broader, continued focus on reducing leverage over the long-term and preserving GNL's balance sheet strength and financial flexibility. Through the transaction, GNL will be acquiring a high-quality industrial net lease portfolio with a 15.0 year weighted average lease term and 2.4% average annual rent escalations, which is expected to extend GNL's weighted average lease term from 5.9 years in Q1'26 to 6.7 years on a pro-forma basis.
"Our recent disposition activity advances our strategy of reducing office exposure while improving overall portfolio quality," said Michael Weil, CEO of GNL. "These dispositions demonstrate our ability to monetize office assets at attractive valuations while redeploying capital into high-quality industrial and retail investments. Together with the pending Modiv acquisition and additional office sales, we expect to reduce our office exposure to approximately 21% of portfolio straight-line rent, down from approximately 26% as of the first quarter of 2026, marking another meaningful step in our ongoing portfolio transformation. We believe these actions will further improve portfolio quality, strengthen our earnings profile, and position GNL to deliver long-term value for our stockholders."
About Global Net Lease, Inc.
Global Net Lease, Inc. (NYSE: GNL) is a publicly traded real estate investment trust that focuses on acquiring and managing a global portfolio of income-producing net lease assets across the U.S., and Western and Northern Europe. Additional information about GNL can be found on its website at www.globalnetlease.com.
Footnotes
[1] Represents dispositions closed from April 1, 2026 through June 26, 2026.
[2] Based on an EUR exchange rate as of June 26, 2026.
Important Notice
The statements in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. The words such as "may," "will," "seeks," "anticipates," "believes," "expects," "estimates," "projects," "potential," "predicts," "plans," "intends," "would," "could," "should" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and other factors, many of which are outside of GNL's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks that any potential future acquisition or disposition by GNL, including the Modiv transaction and the pending KPN disposition and industrial property acquisition, is subject to market conditions, capital availability and timing considerations and may not be identified or completed on favorable terms, or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause GNL's actual results to differ materially from those presented in GNL's forward-looking statements are set forth in the "Risk Factors" and "Quantitative and Qualitative Disclosures about Market Risk" sections in GNL's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in GNL's subsequent reports. Further, forward-looking statements speak only as of the date they are made, and GNL undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
Comcast plánuje oddělit mediální a technologické aktivity do dvou veřejně obchodovaných firem, včetně daňově neutrálního spin-offu NBCUniversal a Sky. Akcie v předobchodní fázi vyskočily až o 26 %.
Comcast said Monday it plans to separate its media and technology businesses into two publicly traded companies as it looks to better compete in a media landscape increasingly characterized by pressure from streaming rivals and consolidation.
The separation, which will happen via a tax-free spin-off of NBCUniversal and Sky, is expected to be completed in about one year, and Comcast shareholders will own shares in both Comcast and NBCUniversal, the company said in a statement.
Comcast shares jumped as much as 26% in premarket trading.
Comcast co-CEO Mike Cavanagh will become CEO of NBCUniversal, while Comcast's former Chief Financial Officer Michael Angelakis will become CEO of Comcast.
Comcast's other co-CEO and chair, Brian L. Roberts, will continue to be actively involved in the leadership of both Comcast and NBCUniversal.
watch now
"The transaction we are announcing will unlock a more entrepreneurial management approach and open up a multitude of new opportunities for each business," Roberts said.
"Comcast will continue to build on its leadership in connectivity, while NBCUniversal, together with Sky, will have the scale, brands, content and financial resources to compete as a premier global media and entertainment company," Cavanagh said.
Comcast said it expects to retain a stake of up to 19.9% ownership position in NBCUniversal for up to one year after the transaction is completed, which it intends to tax-efficiently monetize over time.
It comes as Comcast's share price has plummeted 30% over the past 12 months amid significant challenges facing the media industry that are driven by the shift away from the TV bundle and toward streaming.
Comcast shares over the past year.
Earlier this year, it completed the spin-off of its portfolio of cable TV networks and digital assets, which includes CNBC and MS Now, to the separate public company Versant Media.
The media sector has seen a wave of consolidation recently, as legacy players strive for scale, with few companies going public amid the challenging environment.
Paramount Skydance completed its merger last year, and earlier this month, it won DOJ approval for a $110 billion deal for Warner Bros. Discovery. Meanwhile, Fox entered an agreement to acquire Roku for $22 billion earlier this month.
— CNBC's Lillian Rizzo contributed to this report
Disclosure: Versant is the parent company of CNBC.
Natera a Aveta Biomics uzavřely partnerství pro globální fázi 3 registrační studii AVTA 30-01 s APG-157 u lokálně pokročilého spinocelulárního karcinomu hlavy a krku. Do studie se zapojí Signatera pro sledování molekulární odpovědi a minimální reziduální nemoci (MRD).
Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).
APG-157 is Aveta's first-in-class oral immunotherapy intended to expand the benefits of immunotherapy to both immune-cold and immune-hot tumors in patients with LA-HNSCC. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication.
AVTA 30-01 builds upon previously reported Phase 2 clinical data of APG-157 monotherapy in demonstrating favorable safety, evidence of tumor-control, deep molecular responses, and encouraging event-free survival outcomes. The trial will incorporate serial Signatera testing to assess molecular residual disease (MRD) and treatment response throughout therapy and follow-up. Circulating tumor DNA (ctDNA) has emerged as one of the most promising approaches for detecting MRD and identifying recurrence earlier than conventional imaging alone.
Approximately 826 patients are expected to be enrolled across North America, Europe, Asia-Pacific, and Australia. The study includes separate randomized cohorts for resectable and unresectable locally advanced disease, each with treatment and control arms, and Signatera will be a secondary endpoint. The trial is expected to begin enrollment in 2H’26.
Global annual incidence of head and neck cancer is approximately 950,000,1 and disease recurrence remains a major cause of mortality despite advances in surgery, radiation therapy, and immunotherapy.
“Patients with locally advanced head and neck cancer continue to face substantial risks of recurrence despite aggressive treatment,” said Parag Mehta, Ph.D., founder and chief executive officer of Aveta Biomics. “We believe APG-157 has the potential to transform treatment by activating anti-tumor immunity in both immune-cold and immune-hot tumors. Incorporating serial Signatera testing into AVTA 30-01 will allow us to further validate the ctDNA findings observed in Phase 2 while generating molecular response data that will advance the understanding of treatment benefits for patients and strengthen the regulatory submission.”
This study adds to the evidence Natera continues to generate in head and neck cancer. The company recently announced a successful readout of the prospective Phase 2 SINERGY trial, supporting Signatera MRD-guided treatment in this histology.
“Growing evidence continues to demonstrate the value of Signatera MRD detection in head and neck cancer,” said Eric Matthews, general manager, biopharma, Natera. “We’re pleased to partner with Aveta on AVTA 30-01 to demonstrate how Signatera has the potential to advance the field and improve care for patients.”
References
Sun H, et al. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2025 Sep 25;15:1665019.About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
About Aveta Biomics
Aveta Biomics is a clinical-stage immuno-oncology company advancing first-in-class oral therapies designed to reprogram the tumor microenvironment and expand the benefits of immunotherapy to patients with immune-cold cancers. The company’s lead candidate, APG-157, has received FDA Fast Track and Orphan Drug Designations for head and neck squamous cell carcinoma and is in a global phase 3 registrational trial. APG-157 is also being evaluated across additional oncology indications including high-grade adult glioma and oral dysplasia. For more information, visit www.avetabiomics.com.
Forward-Looking Statements (for Natera)
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Forward-Looking Statements (for Aveta)
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those regarding the impact of the Fast Track Designation, the progress of our clinical trials, potential regulatory approvals, the development and commercial success of our drug candidates, and our strategic goals, reflect our current expectations and involve risks and uncertainties. Actual results may differ materially due to factors such as our ability to advance drug candidates through development and regulatory approval, clinical trial outcomes, competition, and economic conditions. Words like “may,” “will,” “could,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. We caution you not to place undue reliance on these statements, which speak only as of the date they are made. As a private company, Aveta Biomics is under no obligation to publicly update or revise any forward-looking statements to reflect new information or future events, except as required by applicable law.
Trump koupil akcie Axon za až 5 milionů USD dva týdny předtím, než ICE požádala o pětiletou zakázku na Tasery za 220 milionů USD. Načasování vyvolalo otázky ohledně střetu zájmů.
President Donald Trump bought as much as $5 million in shares of Axon Enterprise — maker of Tasers, body cameras and policing software — two weeks before Immigration and Customs Enforcement sought a five-year, $220 million contract that experts told CNBC appeared tailored to the company's weapons.
On Feb. 10, Trump purchased between $1 million and $5 million worth of Axon stock, according to federal disclosures he filed in May. On Feb. 24, ICE posted a notice seeking roughly 17,800 new Tasers, along with unlimited cartridges and training.
The White House has said Trump's assets are held in a trust managed by his children and that Trump's investments are managed by independent third-party firms, not Trump or his family.
"There are no conflicts of interest," spokesperson Anna Kelly told CNBC, calling the scrutiny a "tired narrative" pushed by Democrats.
Trump's disclosures with the U.S. Office of Government Ethics, made public May 14, show more than 3,700 transactions, with the total amount for each listed as a range rather than an exact figure.
Under federal law, presidents are exempt from the criminal conflict-of-interest statute that applies to most executive branch officials.
The ICE notice does not name Axon, which makes about 90% of U.S. Tasers according to investment firm Brown Advisory, but it calls for "conductive-energy weapons" with specifications and capabilities that procurement reviewers and three policing experts told CNBC appeared to match only Axon products. The company already supplies the federal government with Tasers.
If finalized, the purchase would more than quadruple ICE's current Taser arsenal, replacing about 4,300 devices in the field, according to the February notice.
The notice refers to an upgrade to the "T10," Axon's "TASER 10" model, to replace ICE's older "X26P/X2 Tasers," which are also Axon-made. It also specifies features associated with "TASER 10," including a 45-foot range and 10 individually targeted probes — all specifications and capabilities that procurement experts say effectively foreclose other bidders.
There's no evidence Trump was involved in or had knowledge of the procurement process, that contracting officials knew of his stock purchase or that Axon knew that Trump was a shareholder. Trump bought the stock on Feb. 10, but the purchase did not become public until his financial disclosure was released in May. There is no indication Axon had access to non-public information about the president's personal investments.
The ICE notice was part of the standard federal procurement process. Federal procurement records show no contract has been awarded yet, and because the notice was a "Request For Information" rather than a formal solicitation, there is no public record showing which vendors, if any, responded.
Axon did not respond to requests for comment on whether it discussed the potential Taser purchase with ICE, DHS or White House officials before ICE posted the Feb. 24 notice.
The timing of the notice raises questions for ethics and three policing experts in part because of its proximity to Trump's stock purchase.
The president was also carrying out his pledge to enact mass deportations. Trump's Feb. 10 purchase occurred weeks after federal agents in Minneapolis shot and killed two U.S. citizens who were protesting an immigration crackdown in the city. Civil rights advocates have decried the killings of protesters as an overreach of law enforcement.
"What happened [in Minneapolis] showed how ICE agents have a hard job," said Deborah Fleischaker, a former acting chief of staff at ICE during the Biden administration. "The agency has a responsibility to make sure they have appropriate modern tools and training, but it's vital that new purchases are made for the right reasons."
Fleischaker, now a senior advisor for immigration policy and strategy at UnidosUS, said the timing "raises red flags," while cautioning it is impossible to assess from the public record whether anything improper occurred. UnidosUS is a nonprofit, nonpartisan Hispanic civil rights advocacy group.
"It is not smart to buy stock in a company that was impacted by the decisions you would be making at the agency," Fleischaker said. "I would have stayed far, far away from actual impropriety, or the appearance of impropriety."
Read more on Trump investmentsCompany that bet big on Trump-backed crypto says its fortunes have improvedTrump family got about $500M from crypto venture — but investors saw steep lossesTrump Jr. calls banking a 'Ponzi scheme' that forced family to create crypto businessThe Trump family crypto empire looks to Asia: Eric Trump talks Bitcoin in Hong KongTrump family says U.S. dollar needs an upgrade and they are the ones to do itEthics experts said the concern is not proof of wrongdoing, but the appearance of a conflict.
"The concern is that [Trump] bought into a company whose business could grow if his own administration expands immigration enforcement," Jordan Libowitz, vice president of communications at Citizens for Responsibility and Ethics in Washington, told CNBC. CREW is a liberal-leaning, nonpartisan watchdog group on government ethics.
Axon shares rose more than 22% in the month after Trump's purchase, before paring those gains. As of the June 26 close, the stock was up about 7% from his purchase date. If Trump bought near the top amount of the disclosed range, the potential paper gain could be worth roughly $350,000 as of market close on June 26. In the week following ICE's notice for seeking a contract, the company's stock rose more than 34%.
ICE and its parent agency, the Department of Homeland Security, did not respond to requests for comment. CNBC asked the agencies whether the purchase has been awarded, why ICE is seeking such a large expansion, how many vendors expressed interest, whether any company besides Axon could meet the requirements and whether the deal requires DHS secretary-level approval.
A person familiar with the procurement, who spoke on condition of anonymity due to fear of retaliation for discussing the pending ICE notice, said awarding the Taser contract appears to be stalled by its price tag and a shakeup in DHS leadership.
The person said ICE posted the contract notice about a week before then-Homeland Security Secretary Kristi Noem was fired and before she had signed off on it. Under Noem, DHS rules required expenditures over $100,000 to be personally approved by the secretary's office. Homeland Security Secretary Markwayne Mullin canceled the rule in April.
It's unclear what the timeline for awarding the contract is, but the person familiar with the procurement said DHS is expected to continue pursuing a deal.
Axon's growing federal footprintFor Axon, the financial upside may not stop at Tasers.
The roughly $35 billion company's biggest growth engine is the policing infrastructure that can follow weapons purchases: cloud storage, evidence-management systems, body cameras, real-time operations tools and AI products. Policing experts say one-time device orders can turn into a long-term technology relationship.
"If Trump expands ICE, Axon could be selling the infrastructure behind the crackdown," said Matthew Guariglia, a senior policy analyst at the Electronic Frontier Foundation focused on policing surveillance who has written extensively about Axon. "It can sell the cameras, cloud storage, software and AI tools that come with a bigger federal enforcement machine." The nonprofit group advocates for privacy and free speech online.
Axon already has a $370 million DHS body-camera and software contract awarded in 2023, though only about $67.5 million has been obligated so far, according to HigherGov, a government market-intelligence platform that tracks federal contracts and grants.
The potential ICE Taser deal would land as Axon is already riding record demand. The company reported its two highest-revenue quarters on record: $796.7 million in the fourth quarter of 2025, up 39% from a year earlier, and $807.3 million in the first quarter of 2026, up 34%, fueled by Taser sales and fast-growing AI products.
Axon executives told investors in February that DHS contracts are a "major opportunity."
Axon has been staffing up to chase that opening. On a May 6 earnings call, Axon President Joshua Isner said the company had "rebuilt a large portion" of its federal team and hired Claudia Davidson from Palantir, where she spent more than seven years helping expand the data-mining and defense contractor's business with federal agencies.
"We're seeing renewed interest in body cameras and Tasers in federal law enforcement," Isner told investors, adding that Axon's federal business was "trending very much in the right direction" and that, "with a few things going our way, it could be a banner year in Fed."
However, civil liberties advocates warn that ICE is wading deeper into Axon's surveillance ecosystem.
Axon's software works to combine live feeds from body cameras, drones, fixed cameras and other sources. If ICE expands raids and works more closely with state and local police, advocates warn that this kind of system could give federal agents a real-time map of local operations.
"If they are able to plug into Ring cameras, livestreams, body cameras and other local feeds, then suddenly you are not just talking about officer safety or accountability," Guariglia said. "You are talking about a platform that could give federal law enforcement a real-time picture of where people are, what is happening on the ground and how to respond with local precision."
Axon announced a Ring partnership in 2025 that lets Ring users voluntarily share footage with law enforcement through Axon's evidence platform. Axon's Fusus platform separately aggregates shared community cameras, body cameras, drones and other feeds onto a real-time map.
Fleischaker said the proposed Taser use expansion via the DHS contract appears consistent with the Trump administration's broader immigration agenda.
"It indicates what we know from other places, which is that the Trump administration has and will continue to ramp up immigration enforcement beyond levels we've ever seen," Fleischaker said. "That requires lots and lots of enforcement, and they would be procuring Tasers to be a part of that effort."
Politically connectedAxon's growth strategy has also led the company to boost its spending in Washington.
Axon spent nearly $2.5 million lobbying last year, its highest annual total, according to OpenSecrets, a nonprofit organization that tracks political spending. Its targets included legislation and regulation around body cameras, counter-drone technology, digital evidence management and other law-enforcement products it is pushing into federal agencies.
And that push appears to be gaining ground. Congress has proposed a $20 million line item in DHS appropriations requiring the agency to outfit immigration enforcement agents with body cameras, partly as a result of heavy lobbying by Axon, policing experts say.
Democrats have joined the effort, too. Sens. Ruben Gallego and Mark Kelly, both Arizona Democrats, introduced legislation requiring all DHS officers to wear body cameras. The legislation has no Republican support, making it unlikely to advance in the Republican-controlled Senate.
Donors connected to Scottsdale, Arizona-based Axon donated over $20,000 to Gallego during the 2024 election cycle when he ran for the Senate, according to OpenSecrets.
Gallego and Kelly, who have publicly championed body-camera and use-of-force requirements for ICE, did not respond to requests for comment on Axon's position as a likely beneficiary of body-camera mandates.
On Capitol Hill, Democrats have called for body cameras as an accountability measure and as a political bargaining chip with Republicans. For Axon, they are also a gateway product, policing experts say, to tie federal officers to its cloud storage, evidence software and AI tools.
"Body cameras can create a durable technology relationship with law enforcement agencies because the footage has to be stored, managed, analyzed and integrated into broader evidence systems," Guariglia said.
Axon's political spending has also drawn scrutiny from shareholders.
The Nathan Cummings Foundation sued Axon in January to stop the company from excluding a shareholder proposal seeking more disclosure around its political spending.
"Since Trump came into office, Axon has spent enormous amounts of money in politics to curry favor and support contracts and laws that benefit the company," Richard Kirby, a former SEC attorney who represented the foundation in its lawsuit against Axon that settled March 9, told CNBC. "That is exactly why investors need transparency."
Matador Resources oznámila, že její společnost San Mateo Midstream koupí provozní aktiva Cardinal Midstream za 752 milionů USD. Akvizice má rozšířit kapacitu zpracování plynu v Delaware Basin na více než 1 miliardu kubických stop denně.
DALLAS--(BUSINESS WIRE)--Matador Resources Company (NYSE: MTDR) (“Matador” or the “Company”) today announced that San Mateo Midstream, LLC (“San Mateo”), Matador’s 51%-owned midstream joint venture with Five Point Infrastructure (“Five Point”), has entered into a definitive agreement to acquire the operating subsidiaries of Cardinal Midstream Partners, LLC (“Cardinal”), a portfolio company of EnCap Flatrock Midstream, for total cash consideration of $752 million. The transaction is expected to close on or before July 31, 2026, subject to customary closing conditions (the “Cardinal Acquisition”). Matador anticipates the Cardinal Acquisition to be cash neutral for Matador as it expects to use distributions from San Mateo and/or proceeds from the potential drop-down to San Mateo or sale of a portion of Matador’s wholly-owned midstream assets to fund any required cash contributions to San Mateo related to the acquisition.
Cardinal Acquisition Highlights
Complementary Midstream Assets. Cardinal’s midstream assets are complementary to San Mateo’s existing natural gas gathering and processing system and provide San Mateo the ability to move natural gas more easily throughout the northern Delaware Basin in southeast New Mexico and West Texas (see map, Exhibit A). Cardinal’s assets consist of (i) a cryogenic natural gas processing plant complex in Loving County, Texas with a designed inlet capacity of approximately 320 million cubic feet of natural gas per day, and (ii) approximately 145 miles of low-pressure and high-pressure natural gas gathering pipelines located in West Texas and southern Eddy County, New Mexico. The Cardinal plant complex sits on approximately 75 acres with two residue natural gas takeaway connections and four natural gas liquids takeaway connections, providing San Mateo the ability to expand processing capacity in the future. Third-Party Customer Relationships and Volumes. Nine of Cardinal’s natural gas gathering and processing customers would be new natural gas customers for San Mateo. The mix of Cardinal’s major, mid-cap and private Delaware Basin producers is expected to directly increase San Mateo’s customer base, volume throughput and revenue generation from third-party customers. Expanded Scale. The Cardinal Acquisition is expected to increase San Mateo’s designed natural gas processing capacity to more than one billion cubic feet per day and expand San Mateo’s gathering systems to over 800 miles of pipeline. Enhanced Flow Assurance for Matador and Other Customers. The combined natural gas system is expected to provide immediate synergies for San Mateo’s gas gathering and processing system. These expected synergies include the ability to flow volumes between Cardinal’s natural gas processing plant in Loving County, Texas and San Mateo’s existing Marlan Processing Plant and Black River Processing Plant, both located in Eddy County, New Mexico. Once acquired, the Cardinal plant complex in Texas as shown on the map should provide additional options and coverage to producers in the area. Accretive to Adjusted EBITDA and Cash Flows. San Mateo expects the Cardinal assets to be immediately accretive to both San Mateo’s Adjusted EBITDA and cash flows. Adjusted EBITDA from the Cardinal assets is expected to increase to up to $110 million on an annualized basis by 2028 when the Cardinal plant complex is anticipated to be completely full. Financing Highlights
San Mateo expects to finance the Cardinal Acquisition, in part, through a new term loan of up to $650 million under its existing credit facility. This new term loan will be led by PNC Bank, the lead bank under Matador’s reserves-based credit facility, and Truist Bank, the lead bank under San Mateo’s existing credit facility. The new term loan will become due and payable 364 days following the closing of the Cardinal Acquisition. The remainder of the purchase price is expected to be funded through a combination of cash on hand, borrowings under San Mateo’s existing credit facility and capital contributions from its partners. Matador expects to use distributions from San Mateo and/or proceeds from the potential drop-down to San Mateo or sale of a portion of Matador’s wholly-owned midstream assets to fund any cash contribution.
Management Comments
Joseph Wm. Foran, Matador’s Founder, Chairman and CEO and San Mateo’s Founder, commented, “We are very pleased to announce San Mateo’s acquisition of Cardinal Midstream. We believe the acquisition—which is being funded by midstream—is the next step in the growth of San Mateo and a continuation of the strategic vision Matador and Five Point share for our joint midstream business to be a leading midstream company in the Delaware Basin, providing flow assurance to Matador and third-party customers. This transaction was built on relationships. Matador’s relationship with the EnCap Investments L.P. (“EnCap”) team and its affiliated entities goes back decades. We look forward to welcoming and building relationships with Cardinal’s customers and working with the talented Cardinal operating team.
“We believe this acquisition will provide substantial benefits to Matador, Cardinal and San Mateo and their respective stakeholders. Financially, this acquisition is expected to add immediate third-party volumes and cash flows, enhancing both San Mateo’s and Cardinal’s expected outlook for 2026 and beyond. This increased scale further improves San Mateo’s positioning for potential strategic alternatives at the corporate level. Strategically, the Cardinal system effectively “completes the circle” for San Mateo infrastructure in the Delaware Basin. Connecting Cardinal’s natural gas gathering and processing assets to San Mateo’s existing natural gas system is expected to give San Mateo the ability to move natural gas throughout the northern Delaware Basin—north to south or south to north—creating better flow assurance and system flexibility that we believe few midstream providers can match.
“The Cardinal Acquisition is expected to not only provide strategically increased flow assurance to Cardinal’s customers but also to provide natural gas processing for Matador’s development of its recently acquired federal lease acreage in Lea County, New Mexico. Additionally, because Cardinal’s system extends near Matador’s Wolf asset area in Loving County, Texas, San Mateo will be well positioned to provide flow assurance for volumes from this asset area too.
“It is also important to note that “midstream money is being used to fund midstream acquisitions” as any capital contributions from Matador to San Mateo are expected to be paid with either cash distributions from San Mateo and/or proceeds received from the potential drop-down to San Mateo or sale of Matador’s wholly-owned midstream assets. These wholly-owned midstream assets continue to provide critical flow assurance for Matador’s natural gas, oil and water in Matador’s Ameredev area and other locations in Lea County, New Mexico.
“We also express our appreciation to PNC Bank and Truist Bank for their continued support and to each of San Mateo’s lenders that we anticipate participating in the new term loan. This new term loan is expected to effectively provide a bridge to San Mateo’s potential future strategic transactions.
“As we have noted before, San Mateo began as a startup midstream company in 2017 and has grown into one of the premier midstream businesses in the northern Delaware Basin and one of the only midstream companies that provides integrated services for all three streams—natural gas, oil and water. We believe the addition of Cardinal will position San Mateo for its next chapter of growth.”
Advisors
Baker Botts L.L.P., led by Preston Bernhisel, and O’Melveny & Myers LLP, led by Jason Schumacher, acted as counsel to San Mateo on the Cardinal Acquisition. Willkie Farr & Gallagher LLP, led by Nathan Meredith, acted as counsel to Cardinal on the acquisition.
About Matador Resources Company
Matador is an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Its current operations are focused primarily on the oil and liquids-rich portion of the Wolfcamp and Bone Spring plays in the Delaware Basin in Southeast New Mexico and West Texas. Matador also operates in the Haynesville shale and Cotton Valley plays in Northwest Louisiana. Additionally, Matador conducts midstream operations in support of its exploration, development and production operations and provides natural gas processing, oil transportation services, natural gas, oil and produced water gathering services and produced water disposal services to third parties.
For more information, visit Matador Resources Company at www.matadorresources.com.
About San Mateo Midstream, LLC
San Mateo is a midstream joint venture owned 51% by Matador and 49% by an affiliate of Five Point Infrastructure LLC. San Mateo provides natural gas gathering, treating and processing, produced water gathering and disposal, and oil gathering and transportation services to Matador and third-party customers in the Delaware Basin in Southeast New Mexico and West Texas.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. “Forward-looking statements” are statements related to future, not past, events. Forward-looking statements are based on current expectations and include any statement that does not directly relate to a current or historical fact. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “could,” “believe,” “would,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “should,” “continue,” “plan,” “predict,” “potential,” “project,” “hypothetical,” “forecasted” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing and closing of the Cardinal Acquisition; the expected benefits, opportunities and results of the Cardinal Acquisition, including the expected impact on cash flows and Adjusted EBITDA, third-party volumes, system connectivity, flow assurance, expansion opportunities and other anticipated impacts of the Cardinal Acquisition; the anticipated financing of the Cardinal Acquisition, including any bridge term loan or other financing transaction, or the required capital contributions or sources thereof, including any potential drop-down to San Mateo or sale of Matador’s wholly-owned midstream assets; other aspects of the Cardinal Acquisition, including guidance, projected or forecasted financial and operating results, future liquidity and the payment of distributions; and San Mateo’s future growth and potential strategic alternatives. Actual results and future events could differ materially from those anticipated in such statements, and such forward-looking statements may not prove to be accurate. These forward-looking statements involve certain risks and uncertainties, including, but not limited to, the satisfaction of closing conditions for the Cardinal Acquisition; the possibility that the Cardinal Acquisition may not close on the anticipated timeline or at all; the ability of San Mateo to integrate the Cardinal assets and realize the anticipated benefits of the Cardinal Acquisition; the availability and terms of financing; commodity price volatility; operational risks; regulatory changes; risks related to obtaining the requisite regulatory approvals for the Cardinal Acquisition; disruption from the Cardinal Acquisition making it more difficult to maintain business and operational relationships; significant transaction costs associated with the Cardinal Acquisition; the risk of litigation and/or regulatory actions related to the Cardinal Acquisition, as well as the other factors that could cause actual results to differ materially from those anticipated or implied in the forward-looking statements. For further discussions of risks and uncertainties, you should refer to Matador’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of Matador’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Matador undertakes no obligation to update these forward-looking statements to reflect events or circumstances occurring after the date of this press release, except as required by law, including the securities laws of the United States and the rules and regulations of the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
(1) Adjusted EBITDA is a non-GAAP financial measure. Matador and San Mateo define Adjusted EBITDA as earnings before interest expense, income taxes, depletion, depreciation and amortization, accretion of asset retirement obligations, unrealized derivative gains and losses, non-recurring transaction costs for certain acquisitions, non-cash stock-based compensation expense, loss on debt extinguishment, net gain or loss on asset sales and impairments and certain other non-cash items. The most comparable GAAP measures to Adjusted EBITDA are net income or net cash provided by operating activities. Estimated Adjusted EBITDA attributable to the Cardinal assets is presented on an asset-level basis and reflects earnings before interest expense, income taxes, depreciation, depletion, amortization and certain other non-cash or non-recurring items. Matador and San Mateo are unable to provide a reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable GAAP measure without unreasonable effort due to the inherent difficulty in forecasting certain reconciling items.
Acuity uvedla, že poptávka po osvětlení po zimním oslabení sílí a projektový tok se normalizuje směrem ke 4. čtvrtletí. Tržby AIS vzrostly o 14,9 % na 303,5 mil. USD.
Key Takeaways AYI said lighting demand is firming after winter softness, with project flow normalizing into Q4.AIS sales rose 14.9% to $303.5 million, driven by Distech, QSC and open-architecture wins.Acuity cited AIS product launches, data center momentum and organic growth in controllers. Acuity Inc. (AYI - Free Report) used its third-quarter fiscal 2026 earnings call to press a forward-looking message: lighting demand is stabilizing, while Acuity Intelligent Spaces continues to supply the company’s faster-growth engine. Management emphasized execution more than headline beat metrics.
That framing mattered because the quarter again showed a split business. Lighting remained pressured on sales, but AIS expanded at a double-digit rate, and management sounded increasingly confident about growth avenues in controls, OEM channels and data centers.
AYI Sees a Better Setup in LightingChairman, president and CEO Neil Ashe said Acuity Brands Lighting is seeing firmer demand after a softer stretch in the winter months, when conversion rates from quoting to releases ran longer than normal. He said activity is starting to normalize and described project flow as more typical heading into the fourth quarter.
Chief financial officer Karen Holcom added that fourth-quarter sales should rise sequentially from the third quarter, though not necessarily at the same pace as the recent step-up. That outlook stopped short of a broad rebound call, but it marked a more constructive tone than earlier commentary around a tepid market.
The quarter itself still reflected pressure. ABL sales fell 1.9% to $905.2 million, though adjusted operating margin remained a healthy 18.2%. Management tied the sales decline partly to a tough comparison against last year’s tariff-related order pull-forward rather than to a new deterioration in demand.
Acuity Leans Harder on AIS GrowthIf the call had a central growth theme, it was AIS. Sales in the segment climbed 14.9% to $303.5 million, with adjusted operating profit up 22.5% and adjusted operating margin reaching 25.1%, driven by Distech and QSC.
Ashe spent much of his prepared remarks on Distech, arguing that Acuity’s open-architecture strategy is translating into share gains. He cited wins at universities, sports venues, enterprise campuses and data centers while also pointing to OEM manufacturers adopting the Eclipse portfolio for next-generation applications.
Management also highlighted new product cadence inside AIS, including Eclipse Resilience for mission-critical cooling and a preloaded dashboard tied to occupancy and space utilization. The message was that AIS is broadening from controls into a platform story built around edge control, cloud intelligence and occupant experience.
AYI Protects Margins While InvestingThe company’s financial backdrop supported that strategy. Adjusted earnings per share increased to $5.31 from $5.12 a year earlier. The figure topped the Zacks Consensus Estimate of $5.20 by 2.1%. Net sales rose 1.6% to $1.2 billion, which modestly beat the $1.19 billion estimate by 1.1%.
Gross margin remained a notable talking point. Adjusted gross profit margin improved 10 basis points to 50.1%, helped by a richer AIS mix, even as ABL adjusted gross margin slipped 50 basis points to 46.1%.
Ashe said inflation remains present across materials and SG&A, with medical costs one example, but he stressed that recent spending has been concentrated in technology and AI capabilities rather than undisciplined overhead growth. He argued that those investments are already helping gross margin and should create stronger operating leverage when volume improves.
Acuity Keeps Capital Deployment FlexibleHolcom said Acuity’s capital allocation priorities have not changed: invest for growth, raise the dividend, pursue acquisitions and repurchase stock opportunistically. That framework was visible in the quarter’s actions.
For the first nine months of fiscal 2026, Acuity generated $520.2 million in operating cash flow and $461.7 million in free cash flow. It also repaid $200 million of term debt year to date, repurchased about 766,000 shares for $230 million and refinanced its revolver with a new five-year $800 million unsecured facility.
Ashe made clear that acquisitions remain a priority, especially in AIS. But he also underscored selectivity, pointing to QSC as the model for buying quality assets that can perform better inside Acuity’s broader platform.
AYI Uses Q&A to Expand the Data Center StoryAnalyst questions pushed management to define how durable AIS growth is and whether data centers are becoming a more material opportunity. Ashe responded by tying recent momentum to a mix of product innovation, market share gains and expansion into adjacencies such as refrigeration and OEM channels.
On data centers, management sounded more explicit than in prior calls. Ashe said Distech now has both direct digital controllers and PLC controllers, which broadens its ability to serve hyperscalers, while the lighting side is also seeing rapid percentage growth off a smaller base.
The answer that stood out most was management’s insistence that this push is currently organic. Ashe said the company’s entry into the data center market is being driven by internal product development, not by a need to buy its way in.
Acuity Leaves the Call With a Clearer ToneThe call ended with a more confident posture than the raw ABL sales number alone would imply. Management’s emphasis was on normalization in lighting, continued margin discipline and a wider runway for AIS.
Ashe also pointed to internal priorities that framed Acuity’s next phase: deploying AI inside the business, accelerating product velocity, improving digital manufacturing and pursuing targeted AIS expansion. Those comments reinforced a company trying to compound operational discipline with higher-value technology exposure.
Zacks Signals Still Call for SelectivityAYI currently carries a Zacks Rank #3 (Hold), alongside Value and Growth Scores of B, a Momentum Score of F and a VGM Score of C. Under the Zacks framework, a Zacks Rank #1 (Strong Buy) and #2 (Buy) stocks paired with Style Scores of A or B offer the strongest near-term setup, while a Rank #3 is generally more neutral. You can see the complete list of today’s Zacks #1 Rank stocks here.
That mix points to a stock with some supportive value and growth characteristics, but weaker momentum. The Zacks methodology also treats estimate revisions as the primary driver, which means the current rank can change after analysts update forecasts following the quarter.
Korn Ferry uzavřela definitivní dohodu o převzetí AMS za zhruba 850 milionů GBP. Spojením vznikne globální lídr v talentovém a organizačním poradenství.
LOS ANGELES--(BUSINESS WIRE)--Korn Ferry (NYSE: KFY), a global organizational consulting firm, today announced that it has entered into a definitive agreement with OMERS Private Equity to acquire UK-headquartered AMS, which will create a global leader in talent and organizational consulting.
The combination will bring together two highly complementary organizations across geographies and industries with a shared commitment to drive business performance. Following completion, the collective firm will have more than 16,000 colleagues placing a professional in a job approximately every 90 seconds.
“By bringing AMS into the Korn Ferry family, we are expanding our ability to help clients solve their most critical organizational challenges,” said Gary D. Burnison, CEO, Korn Ferry. “Despite all of the technological innovations of yesterday, today and tomorrow, the real driver of organizational success is people. And with our AMS colleagues we will be stronger together than apart. Over almost 20 years I have watched AMS grow and evolve, with deep admiration and respect. I am convinced that the culture and values of both companies are completely aligned. And it all starts with people. This is indeed a significant milestone for Korn Ferry and I am excited about the future that we will shape together.”
The transaction will combine Korn Ferry’s expertise across Search, Talent & Organizational Solutions, and Workforce Solutions with AMS’s highly regarded expertise in Recruitment Process Outsourcing (RPO), Early Careers and Campus Recruiting, Contingent Workforce Solutions, Consulting, and Skills Creation.
“At AMS we connect organizations with the people who advance their vision and deliver their purpose—powering industries, achieving results and shaping futures,” said Rosaleen Blair, Founder and Chair of AMS. “In Korn Ferry we have a like-minded partner that shares the same beliefs and embraces the same values.” Following the consummation of the transaction, Rosaleen Blair will continue in a Chair role.
“Combining AMS with Korn Ferry will create new opportunities for our clients, our teams, and accelerate our ability to shape the future of work,” said Gordon Stuart, CEO of AMS.
“AMS has made incredible progress over the course of our ownership,” said Michael Block, Head of Private Capital, OMERS. “We have supported the company as it has expanded its capabilities, strengthened its client relationships and focused on the people and organizations it serves. Korn Ferry is a strong strategic fit for AMS as it enters its next chapter.”
Founded by Rosaleen Blair in 1996, AMS serves many of the world’s leading organizations across financial services, technology, healthcare, life sciences, consumer, industrial, and public sector markets. Its operations span more than 120 countries, including a well-established presence throughout Europe and Asia.
Drawing on the totality and strength of both firms—and leveraging combined expertise and relationships across geographies, the combined company will create more sustainable opportunities at scale.
Terms of the Acquisition Agreement
Under the terms of the acquisition agreement, Korn Ferry has agreed to acquire AMS for an aggregate purchase price of approximately £850 million (approximately $1.1 billion), consisting of (i) approximately £659 million (approximately $881 million) in cash and (ii) approximately £191 million (approximately $255 million) in Korn Ferry common stock.1
Korn Ferry expects to fund the cash portion of the transaction consideration with approximately $300 million of cash on hand and the remaining approximately $581 million of cash consideration with borrowings under Korn Ferry’s existing revolver. Additionally, Korn Ferry will issue approximately 3.6 million shares2, subject to a 15% collar at the closing.
On a current annual run-rate basis, AMS is generating approximately $650 million of Fee Revenue and $100 million of Adjusted EBITDA.3 Assuming no adverse change in the economic environment, Korn Ferry estimates that the run-rate Adjusted EBITDA3 contribution within a year following the closing of the acquisition will be approximately $140 million.
The consummation of the transaction is subject to receipt of regulatory clearances and is expected to close in Korn Ferry’s 2nd fiscal quarter of FY’27. The transaction is expected to be immediately accretive to earnings per share in the first full year after adjusting for restructuring and integration and transaction costs.
AMS’s long-term contracts will add more than $1.5 billion in estimated fees remaining under existing contracts, providing greater revenue visibility and enhancing the Company’s ability to provide scalable, data-driven talent strategies across geographies and industries.
Additional details regarding the transaction will be discussed during a conference call with investors on Monday, June 29 at 8:30 a.m. EDT. The call will be webcast and available online at www.kornferry.com under Investor Relations, News & Events.
About Korn Ferry
Korn Ferry is a global consulting firm that powers performance. We unlock the potential in your people and unleash transformation across your business—synchronizing strategy, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. That’s why the world’s most forward-thinking companies across every major industry turn to us—for a shared commitment to lasting impact and the bold ambition to Be More Than.
As the Official Talent & Organizational Consulting Partner of LA28, Korn Ferry is powering the nearly 5,000 people who power the Olympic Games—bringing in the right talent, building strong leaders, and shaping the structure and culture that will deliver an unforgettable experience for the world.
About AMS
We are people experts.
Our 8,000 colleagues power talent acquisition and consulting strategies that deliver results for leading organizations across 120 countries.
We partner with our clients to help re-define a new era of talent, driven by people, process, data and technology, enabling them to attract and retain the talent they need to achieve their vision.
Our core areas of service include: Recruitment Process Outsourcing (RPO), Early Careers and Campus Recruiting, Contingent Workforce Solutions, Consulting and Skills Creation, which are amplified by digital capability and strategic technology partnerships.
We call this...People powered partnership.
Forward-Looking Statements
Statements in this press release and our conference call include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 concerning the transaction. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “may,” “plan,” “outlook,” “project,” “will” or other similar expressions. Such forward-looking statements include, but are not limited to, statements relating to the USD converted purchase price, the number of shares of Korn Ferry stock to be issued in the transaction, the timing of the transaction, the expected benefits of the transaction, including the global leadership position of the combined company, the combined company’s expanded capabilities, transaction synergies, future financial and operating results, and the combined company’s plans, objectives and expectations. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. Such risks and uncertainties, many of which are outside of the control of Korn Ferry, include, but are not limited to: (1) the occurrence of any event or change that could give rise to the termination of the acquisition agreement; (2) the inability to timely complete or complete at all the transaction; (3) delays in obtaining or the inability to obtain, necessary regulatory approvals; (4) the risk that the transaction disrupts current plans and operations of Korn Ferry and/or AMS; (5) the ability to successfully integrate the operations and employees of AMS into Korn Ferry; (6) the ability to recognize the anticipated benefits of the transaction which may be affected by, among other things, the ability of Korn Ferry and AMS (prior to the closing) and the combined company (following the closing) to maintain relationships with clients and suppliers and retain key employees; (7) currency exchange rates; (8) fluctuations in Korn Ferry’s stock price; (9) costs related to the transaction; (10) the outcome of any legal proceedings that may be instituted against Korn Ferry or AMS or their respective affiliates following announcement of the transaction; (11) the possibility that Korn Ferry or AMS may be adversely affected by economic, business, and/or competitive factors; and (12) other risks and uncertainties indicated from time to time in filings with the SEC by Korn Ferry. Korn Ferry undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities.
Alphabet klesl o dvouciferné procento v posledních týdnech, ale Warren Buffett a Greg Abel zůstávají klidní. Firma dál zvyšuje investice do AI infrastruktury a poptávka po ní je podle ní rekordní.
Last year, Warren Buffett corrected one of his previous investing mistakes. He initiated a sizable position in Google parent Alphabet (GOOG 2.15%) (GOOGL 1.73%), several years after admitting that he regretted not buying the stock earlier.
After Buffett stepped down as Berkshire Hathaway's (BRKA +1.60%) (BRKB +2.08%) CEO at the end of 2025, his successor, Greg Abel, more than tripled the conglomerate's stake in Alphabet. The stock now ranks as Berkshire's fifth-largest holding.
But Google's stock has fallen by double digits over the past few weeks. Are Buffett and Abel worried that they made a mistake buying the stock? I don't think so. If you own shares of Alphabet, here's why you shouldn't be worried, either.
Image source: Getty Images.
Why the stock's decline isn't really scary Three factors explain Alphabet's decline since May. None of them should be scary to investors, in my opinion.
First, Alphabet's first-quarter update revealed another significant increase in planned capital expenditures. The company provided capex guidance of $180 billion to $190 billion for full-year 2026. Some investors have become jittery over the sky-high spending on artificial intelligence (AI) infrastructure by Alphabet and other tech giants.
Second (and related to the first factor), Alphabet announced in June that it was raising $80 billion through private placement equity offerings. The company said that these offerings are part of the plan "to fund investments in its world-class AI compute infrastructure to meet its unprecedented customer demand."
Third, two high-profile defections last week caused the stock to experience its worst day in more than a year. Noam Shazeer, Google's vice president of engineering and one of the leaders of the Gemini AI models, announced he was leaving to join OpenAI. Two days later, Google DeepMind vice president and engineering fellow John Jumper announced that he was leaving to join Anthropic. Jumper received a Nobel Prize with Google DeepMind CEO Demis Hassabis for developing AlphaFold, an AI system that predicts protein structures.
Anat Askkenazi, CFO of Alphabet and Google, said in the Q1 update that the company continues to see "unprecedented internal and external demand for AI compute resources." Ashkenazi pointed out that investments in AI infrastructure are driving record revenue and backlog growth.
What about the departures of key AI leaders? It is somewhat concerning. However, this kind of musical chairs is commonplace in the industry. Alphabet still has a huge level of AI talent and the money to recruit more people.
Today's Change
(
-1.73
%) $
-5.95
Current Price
$
337.76
I have no doubt whatsoever that neither Buffett nor Abel is losing sleep over the factors behind Alphabet's recent sell-off. For one thing, Abel led the charge for Berkshire's additional $10 billion investment in Alphabet that was part of the private placement. If he had any qualms about Alphabet spending more on AI infrastructure, he would never have committed such a significant amount of Berkshire's capital.
It's important to remember Buffett's perspective on stock declines. At Berkshire Hathaway's 2010 annual shareholder meeting, he said, "If you have a temperament that when others are fearful you're going to get scared yourself, you know, you are not going to make a lot of money in securities over time, in all probability."
What's more, the legendary investor gave a decidedly contrarian opinion. He stated that some investors buy a stock and then "think if it goes up it's wonderful, and if it goes down it's bad." Buffett explained, "We think just the opposite. When it goes down, we love it, because we'll buy more. And if it goes up, it kills us to buy more."
An opportunity for long-term investors As usual, Buffett was right. A pullback in a wonderful company's share price presents an excellent buying opportunity for long-term investors. And Alphabet remains a wonderful company.
The record Google Cloud backlog provides excellent revenue visibility. Google Search continues to grow, with generative AI serving as a tailwind rather than the "Google killer" some predicted. Waymo is the leader in autonomous ride-hailing. Alphabet is even now part of the Dow Jones Industrial Average (^DJI 0.09%), reflecting how important it has become to the U.S. economy.
Don't be surprised if Berkshire's next 13-F filing reveals that the conglomerate took advantage of Alphabet's decline to load up on more shares. After all, that's the Warren Buffett way.
Nvidia rozšiřuje tým pro Space-1, svůj první výpočetní systém pro vesmír. Nová role má pomoci vytvořit software pro orbitální datová centra a provoz na nízké oběžné dráze.
Nvidia CEO Jensen Huang. Bloomberg/Getty Images Nvidia's AI ambitions are officially out of this world this year, and they haven't come back down to Earth.
The AI chip giant is adding to the team behind Space-1, its first computing system designed for space. In recent weeks, the chip giant posted a second job tied to orbital data centers.
The role — for a system software principal architect — will help build software for Space-1, which the chip giant unveiled at its GTC event in March.
Space data centers have emerged as a potential way to get around growing constraints on land, power, and cooling on Earth. Companies like SpaceX are racing to make the idea a reality, while skeptics argue the costs still outweigh the benefits.
During a recent earnings call, Nvidia CEO Jensen Huang said the economics around space computing are poor today but will improve over time.
The principal architect job post follows another role shared earlier this year for an orbital data center system architect. While that position focuses on designing the overall system — from computing hardware to satellites to connectivity systems — the new post focuses on making Space-1's software work in practice.
The person hired will design the software that runs the system so it can withstand radiation and extreme temperature swings and be managed remotely.
Space-1 harnesses Nvidia's latest Vera Rubin AI chip platform and is designed for low-Earth orbit missions.
The system software role requires previous experience building AI infrastructure and systems in space. It offers a base salary of $272,000 to $431,250, which doesn't include Nvidia's coveted equity awards.
While the technology is still in its early stages, Nvidia's latest job postings suggest the chipmaker is moving from conceptual planning to building the systems needed to make it work.
Have a tip? Contact this reporter via email at [email protected] or Signal at @geoffweiss.25. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Geoff Weiss You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Geoff Weiss is a senior reporter on Business Insider’s tech team, where he writes about AI startups and Y Combinator, the intersection of AI and the media industry, and workplace dynamics within top AI labs and chip companies.Previously, Geoff was on the media desk, covering YouTube and Netflix, and themes like the intersection of Hollywood and the creator economy. His work on Netflix’s video podcasting ambitions and Mr Beast’s lessons for Hollywood won second and first prize, respectively, at the 2025 LA Press Club Awards.Prior to joining Business Insider, Geoff was the senior editor of Tubefilter and a staff writer at Entrepreneur. He graduated from New York University with a degree in English Literature.He can be reached at [email protected], on Signal @geoffweiss.25, and on LinkedIn. Have a tip? Use a personal email address and a nonwork device; here's our guide to sharing information securely.Selected stories:Nvidia crushed its quarter — and CEO Jensen Huang said in a leaked all-hands that 'the market did not appreciate it'Nvidia will foot the bill for Trump's new visa fees. Here's what CEO Jensen Huang told staff.Massive AI salaries and RTO are fueling a real estate boom in San Francisco: 'It's going to rain money'The AI talent wars are ricocheting across startups. Here's how they're competing with Big Tech.
